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When a health authority approves a drug for marketing, they approve the
drug for use in the population tested by drug manufacturer. However, once the
drug is on the market, a physician may legally prescribe the drug in whatever
manner they feel is appropriate for their patients. When the drug is prescribed in
a manner outside of the marketing approval, it is prescribed in an off-label
manner. Off-label prescribing is prevalent in many populations, including up to
80% of the drug prescribed to children.
The purpose of this study was to determine the beliefs and experience of
pediatricians toward this practice. A total of 167 pediatricians answered an 11
question survey regarding their beliefs and experience with off-label prescribing.
The results indicated that pediatricians are concerned with the safety and
efficacy of drugs that are prescribed in an off-label manner and they believe that
more references should be available to determine the best medicines to
prescribe to their patients. In addition. respondents are concerned about the

13
legal liabilities, patient complaints, and insurance coverage related to off-label
prescribing.
As this study is the first to determine the beliefs and experience of
pediatricians toward off-label prescribing, the results provide a foundation for
pediatricians to develop effective guidance and improve their clinical judgment
when prescribing medicines off-label.
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Chapter I

Introduction

Background of the Problem
Prior to marketing a medicine to a specific population, pharmaceutical
manufacturers must submit evidence to a regulatory health authority indicating
that the medicine is both safe and effective for that population. The evidence
required by the health authority includes data from tests in humans, which are
collectively known as clinical trials. If the results from the clinical trials indicate
that the benefits of the medicine outweigh the risks, the regulatory authority
generally approves the medicine for the specific indication, population, route of
administration and dosage studied in the clinical trial. However, once the
medicine is approved for a single indication, population, route of administration
and dosage, any physician may legally choose to prescribe the drug in a manner
not approved by the regulatory authority (Cohen, 1997).
When a medical practitioner prescribes a drug for an indication, dose,
population or route of administration not indicated on the drug's label (I.e. in a
manner not approved by a regulatory authority), they have prescribed the drug in
an "off-label" manner. Many people believe that because medicines prescribed
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off-label are not tested in a clinical trial that the patients may be at a higher risk
for safety concerns or that the medicine may not be effective for the prescribed
use (Cohen, 1997).
There is some research that indicates that even though they prescribe
medicines off-label, some physicians may not be aware of the practice of offlabel prescribing. For example, the results of one study indicate that about 1 in 4

I
~

physicians were not familiar with off-label prescribing, and that only 40% of
physicians knowingly prescribed medicines off-label (Ekins-Daukes, Helms,
Taylor & McLay (2005)). This lack of off-label prescribing practices combined
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with the fact that many medications may not have sufficient evidence to support
its usage in the manner it was prescribed, could limit health care management
options and or put patients at increased risk for adverse effects resulting from the
management practices implemented.
Additional risks exist when the patient receiving the off-label medicine is a
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child because children have more active physiological changes than adults

I

j

t

1
I

(Cohen, 1997). However, up to 80% of medicines prescribed to children are offlabel (Pandolfini & Bonati, 2005; Shah, et aI., 2007). Although there are no
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studies that indicate exactly why off-label prescribing is so prevalent in this
population, Conroy (2002) argues that the pediatricians who are aware of the
practice and knowingly prescribe medicines off-label may do so because

!
4

I
j

!
J

I
J

information on the proper use of the medicine is not available. O'Reilly & Dalal
(2003) further suggest that a pediatrician may prescribe a medicine off-label
because there is a lack of adequate information regarding the appropriate use,
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safety and efficacy of the medicine, a medical practitioner's fear of litigation if the

1

medicine they prescribe is not approved for the use prescribed, whether the

I

patient has insurance coverage for the preferred medicine or whether a patient
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has complaints regarding the use of off-label medicines to treat their disease.
The information is not available because, often, drug manufacturers do not
perform clinical trials in a certain population, such as children, because the cost
of performing the research outweighs the potential marketing value - the
pediatric population is relatively small compared to the adult population for most
diseases. To encourage drug manufacturers to perform clinical trials in the
pediatric population, in 1997, the FDA enacted the pediatric exclusivity program.
This program allowed the FDA to grant an extra six months of patent rights to
companies that performed clinical trials in children. For many medicines, an
extra six months of patent exclusivity could mean up to half a billion dollars in
additional sales of the medicine and more than cover the cost of the research.
While the purpose of this program was to encourage pharmaceutical
companies to perform more clinical trials in children, thus enabling physicians to
have more information on how to prescribe the medicine in the pediatric
population. While the program incentives successfully encouraged
pharmaceutical manufacturers to perform over 250 additional studies in children
between 1998 and 2004, there was no incentive for the manufacturer to publish
the study results. Benjamin, et al. (2006) found that the clinical trial results were
published in peer-reviewed journals less than half of the time. Thus the lack of
published results restricts the establishment of evidence-based practice. Often,
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the drug studied may have been on the market for a while and the manufacturers
may not believe that publication was a worthwhile investment of resources.
Therefore, any negative results or results that are not published or do not lead to
a change in the drug's label, may never reach the physician prescribing the
medicine to determine the appropriate use of the medicine for their patient
(Benjamin, et al. 2006).
Unfortunately, even if proper pediatric prescribing information is available,
it may not be present in the medical drug references most often utilized by
physicians. Therefore, physicians may not be aware of the proper current use of
a medicine. For example, greater than 70% of the entries in the Physicians Desk

Reference (PDR), a popular reference used in the United States, have either no
pediatric dosing information or an explicit statement saying that safety and
efficacy in children has not been determined (Blumer, 1999). Moreover, the
results of a survey given to 500 family physicians in Canada indicated that the
reference used by 87% of the physicians, the Compendium of Pharmaceuticals

and Specialities, did not reflect the current pediatric standard of care (Matsui,
Jardine, Steer, Cukernik & Rieder (2003)).
Another concern with off-label prescribing is insurance coverage. Many
prescription benefit companies will reimburse patients only for drugs that have
been approved by the FDA for the use in which they were prescribed (O'Reilly &
Dalal, 2003). In situations where off-label treatments may be more effective than
approved drugs, reimbursement issues can hinder a physician's ability to
effectively treat a patient. Patients in these situations may be forced to pay out
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of-pocket for their drugs or be treated with drugs that may be less effective for
their situation.
Accordingly, physicians also fear litigation when prescribing a medicine
off-label (Hill, 2005; O'Reilly & Dalal, 2003). Although off-label prescribing is
legal, physicians must use their professional judgment, based on the scientific
literature and their personal experience, when choosing to prescribe a medicine
in an off-label manner. If a physician is sued for prescribing a medicine off-label,
it is his/her responsibility to prove that prescribing the-medicine was most
appropriate choice for their patient. Some commonly used references may not
have the complete prescribing information for a medicine so proving proper use
of the medicine may be difficult. Therefore, even if a physician believes that an
off-label medicine may be more appropriate for their patient, they may fear
litigation and possibly withhold a better treatment from their patient (O'Reilly &
Dalal, 2003).
Physicians also want to please their patients when prescribing medicines.
Lowe-Ponsford & Baldwin (2000) surveyed 200 psychiatrists to determine how
common off-label prescribing was in their specialty and to ascertain whether or
not they felt sufficient prescribing guidelines were available. Although 65% of
respondents had prescribed medicine off-label in the last month, only four
percent had received complaints from their patients regarding the off-label
prescribing. The respondents did not indicate the context of the specific
complaints but the authors believe that, based on respondent comments,
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whether a patient complains about the use of a drug off-label may be another
factor that influences physicians to prescribe a medicine off-label.
Most importantly, previous studies report that off-label treatments can lead
to a higher incidence of adverse drug reactions (ADRs). Turner, Nunn, Fielding,
and Choonara (1999) found that patients who were prescribed a drug off-label
had a 1.5 times greater chance of an ADR than those who were prescribed drugs
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according to their marketing license. Choonara and Conroy (2002) argue that
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because children have a significantly different physiologic and metabolic makeup
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than adults, medicines may severely affect their physical and metabolic status.
In fact, the results of a survey of 257 hospital-based pediatricians indicated that
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about half of pediatricians were concerned about efficacy and safety of off-label
medicines (McLay, Tanaka, Ekins-Daukes & Helms (2006». Therefore, patient
safety concerns in the pediatric population are paramount.

Purpose of this Study
Because the physician ultimately decides what medicine to offer what
patient, it is important that their perspectives of off-label prescribing practices are
understood. This is especially important in the treatment of children, whose
maturing bodies may be more sensitive to the medicine's effects. The results
from this study will provide an understanding of factors that influence a
pediatrician's decision to prescribe a medicine off-label and thus may lead to
strategies for promoting more informed off-label practices amongst pediatricians.

Research Question

20
What factors influence a pediatrician's decision to prescribe medicines off
label?

Hypotheses
•

Pediatricians will report that the primary factors that influence their
decision whether or not to prescribe a medicine off-label are:
o lack of appropriate references
o concerns about patient safety.

•

Pediatricians will report that the secondary factors that influence their
decision whether or not to prescribe a medicine off-,Iabel are:
o legal concerns
o insurance coverage
o patient complaints.
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Chapter II

Review of Literature

A license to market a medicine in the United States is given to a
pharmaceutical manufacturer only after they provide sufficient data to the FDA
that the medicine is safe and effective for a particular use in humans. The
process for gathering these data to submit to the FDA is outlined in the first
section of this literature review.
Once the product license is granted by the FDA to the manufacturer,
physicians may legally prescribe the medicine in any manner, whether or not it is
indicated on the product license. If the medicine is prescribed outside of its
product license, it is prescribed in an off-label manner. The second section of this
literature review describes the prevalence of off-label prescribing in many
populations, including children, the target population of this study.
Although off-label prescribing is, in many cases, the standard of care for
some patients and diseases, there are risks associated with the practice,
especially for the pediatric population. The third portion of the literature review
describes these concerns and risks from both the patient and physician point of
view.
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The final portion of this literature review explains the FDA efforts to
encourage pharmaceutical manufacturers to collect data about the use of their
medicines in children with hopes that the additional data collected from these
studies can allow physicians to make more informed decisions about the use of
the medicine in this population.

The Drug Development and Approval Process
When a drug manufacturer develops a new medicine, it must be approved
by the FDA prior to marketing in the United States. FDA approval is given only
when a manufacturer can prove that the benefits of the drug outweigh the risks
and that the drug is safe and effective for human use. In order to determine the
safety and efficacy of a drug, a drug manufacturer must perform several tests
using the drug. The results of these tests allow the FDA to determine whether or
not the drug should be approved for use. Blumer (1999) and Kaitin & Healy
(2000) describe how the typical drug development process encompasses several
unique steps: pre-clinical testing, clinical testing, approval and post-marketing.
Figure 1, which is based on their research, summarizes the cost, time and
resources required for each step of the drug development process and how the
steps relate to one another.
Pre-clinical testing. Once a chemical entity that has some beneficial
effects on a disease target is discovered, a drug manufacturer performs preclinical tests using the molecule. These tests, which usually last between 3 and
6 years, are performed using various laboratory and animal models and their
purpose is to determine initial safety and efficacy profiles of the medicine.
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Clinical testing. If the results from the pre-clinical tests indicate that the
medicine is safe and effective, a drug manufacturer may apply for an FDA
Investigational New Drug Application (IND). Approval of the IND allows the
manufacturer to begin clinical trials. There are three phases of clinical trials
during the clinical testing portion of the drug development process. The three
phases together can last from 2-6 years.

Phase I clinical trials. The first time the medicine is tested in humans is
during phase I clinical trials. The purpose of phase I clinical trials are to
determine the safety, pharmacokinetics and pharmacodynamics profiles of the
medicine. Therefore, the participants in these trials are healthy volunteers and
not patients who need the medicine for therapy. Typically 20-100 participants
are involved in phase I trials.

Phase /I clinical trials. The first time the medicine is tested in patients
who have the disease to be treated is during Phase II clinical trials. The primary
purpose of phase II trials is to determine the efficacy profile of the medicine.
Dosing, kinetics and metabolism of the medicine are further studied in these
trials. Typically, 100-500 patients are enrolled in these studies.

Phase 11/ clinical trials. The purpose of phase III clinical trials is to
further evaluate the safety and efficacy of the medicine in patients with the
disease to be treated. Phase III clinical trials involve many more participants
than in the previous two phases, typically 1,000 to 5,000 patients.
New Drug Application and approval process. Once the manufacturer
has enough data to support marketing the medicine, they must submit a New
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Drug Application (NDA) to the FDA. The NDA contains the data gathered from
both the preclinical and clinical tests performed. The FDA takes an average of
1.4 years to grant approval to the manufacturer. Once the medicine is approved
by the FDA, the manufacturer can legally market the medicine in the United
States, but only for the population(s) and indication(s) tested in clinical trials with
positive results.

Post marketing (Phase IV clinical trials). As clinical trials are
performed over a specific and relatively short duration with a relatively small
population, the safety and efficacy profiles of the medicine may not be fully
known at the time the medicine is approved. Once a medicine is on the market,
a manufacturer may choose to (and sometimes may be forced to by the FDA)
perform phase IV clinical trials to further evaluate the medicine for the already
approved use or new uses once it is on the market. The results of these clinical
trials are often used to expand the information on the original label, with FDA
approval.

I
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Figure 1. The steps of the typical drug development process, their
relationship to one another, their purpose, and the average time, cost and
patients required for each step.
PRE-CLINICAL TESTING
~ - Food and Drug Adrrinistration
If\[) - ~vestigational New Drug Application
NJA - New Drug Application

-Drug Discovery
CLINICAL TES1·ING

-Animal Testing

Phase I:
20-100 healthy volunteers
AJrpose: initial safety, biological effe~c~_
rretabolism, kinetics
Phase II:
100-500 patient volunteers
________ ',",DIIi8"
AJrpose: efficacy, dosing, kinetics,
~4Ict.
rretabolism
Phase III:
~
1000-5000 patient volunteers
AJrpose: safety and efficacy

'or .

I

I

13-6 years

2-6 years

POST MARKETING
Phase IV:
_

Patients given drug for
therapy
AJrpose: adverse

1 ,.act'm,. pattem,.

additional indications

Awrage 1.4 years .

Awrage cost $800 million

Prevalence of Off·label Prescribing
A medicine is prescribed off-label when it is prescribed outside of its
product license with respect to the dosage, age, indication and/or route of
administration. Determining the prevalence of off-label prescribing can be
difficult for a researcher because all of these factors may not be known to the
researcher at the time of the study. For example, a researcher may be able to
easily determine if the dosage was prescribed according to the product label by
comparing the label to the dosage given, but it may be difficult, due to privacy
laws, for a researcher to determine the age or indication of the patient who
received the medicine.
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Studies conducted in various populations determined that medicines are
prescribed off-label 20-90% of the time. The majority of these studies reviewed
only one or two conditions for determining whether or not a medicine was
prescribed off-label (e.g. only indication or only patient age or both). In addition,
the literature suggests that the greatest prevalence of medicines prescribed offlabel is to patients in the hospital and to children with serious or rare diseases
(O'Reilly & Dalal, 2003).

Patient location. When comparing the prevalence of off-label prescribing
between in-patients and out-patients, research suggests that the lowest
percentage of off-label prescribing occurs in the outpatient setting. Radley,
Finkelstein and Stafford (2006) performed a retrospective analysis of United
States prescribing data to determine the rate of off-label prescribing among
office-based physicians. The researchers reviewed prescription data from the

I
1

National Disease and Therapeutic Index (NDTI), a national survey that requires
office-based physicians to report all diagnoses and drug therapies for every
patient encounter during two randomly selected consecutive workdays. Of the

j

total of 725 million prescriptions analyzed, the authors found that 21 % (150

I

million) were prescribed off-label due to the indication they were used to treat. In
addition, the authors determined that out of the 150 million prescriptions, only

I

27% had strong scientific support for the use in which they were prescribed.

j

On the other hand, in the largest study of off-label prescribing in the
United States pediatric population to date, Shah, et al. (2007) reviewed
prescriptions from a database containing demographic information, diagnoses
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and procedures for all patients discharged from 31 pediatric hospitals in the
United States. In order to determine the prevalence of off-label prescribing, the
authors compared the patient's age with the FDA approved age range for any
indication of the medicine. Out of a total of 355,409 patients, 297,592 (78.7%)
received at least one medicine off-label indicating that off-label prescribing is
especially prevalent in the pediatric inpatient population.

Patient diagnosis. The prevalence of off-label prescribing can vary due
to the patient's disease, regardless of their age. Sugarman, Fletcher and
Feldman (2002) reviewed 7 years of data from a United States National Center
for Heath Statistics survey to determine the prevalence of off-label prescribing for
dermatologic diseases in adults. For approximately 200 million office visits
where the primary and only diagnosis was dermatologic, the researchers
compared the patient's diagnosis to the medication prescribed to determine
whether the medicine was prescribed off-label. Depending on the diagnosis, up
to 73% of prescriptions were prescribed off-label.
Loder and Biondi (2004) prospectively studied off-label prevalence rates in
an adult specialty headache practice in the United States over a 30-day period.
During the study, physicians were instructed to record the medication(s)
prescribed and whether they were prescribed according to the FDA-approved
package insert. In total, 379 eligible prescriptions were written during the study
period and 178 (47%) were prescribed off-label.
Researchers report similar results regarding the prevalence of off-label
prescribing in different diseases in the pediatric population as well. Johnson and
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Clark (2001) performed a prospective study of medicines prescribed by child and
adolescent mental health practitioners in England over a six month period. When
prescribing a new medicine to their patient during the study period, the
prescribing clinician recorded the age of the child, the drug prescribed, the
maximum dosage prescribed and the condition being treated. Out of the 478
new medicines prescribed during the study period, 39% were prescribed offlabel.
Conroy, Newman and Gudka (2003) also prospectively studied pediatric
off-label drug use in the United Kingdom. However, they reviewed prescription
data for pediatric oncology inpatients and outpatients of a medical center during
a 4 week period.

During the study period, the researchers collected the

patient's hospital number, age, weight, surface area, diagnosis, drugs
administered, formulation, date and route of administration, dose, frequency and
indication for use. Although they collected more data on their patients than
Johnson and Clark (2001), which would allow them to determine that a medicine
was prescribed off-label for more reasons (e.g. route of administration) they
found that only 26% of the medicines prescribed were off-label.
Lastly, 't Jong, Eland, Sturkenboom, van den Anker and Stricker (2004)
retrospectively reviewed a random sample of patient data 'From a database of
prescription data from a group of 150 general practitioners in The Netherlands to
determine the prevalence of off-label prescribing of respiratory drugs given to
children during a one year period .. The data reviewed included the name of the
medicine, dosage, indication and patient age. Of the of 5,253 respiratory drugs
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issued to 2,502 patients during the study period, only 20.3% were off-label, even
less than the prevalence found in the Conroy et al. and Johnson and Clark
studies.
The results of each study reviewed vary significantly because the authors
of each study used different methods for determining whether a medicine was
prescribed off-label. Also, the duration of the study, whether it was retrospective
or prospective, the location of the physicians, and the specific disease studied
explain the variance as well. In any case, these studies indicate that off-label
prescribing is prevalent in a variety of geographic locations (United States,
United Kingdom, and The Netherlands), indications (dermatology, headache,
mental health, oncology, and respiratory diseases) and patient populations
(adults and children).
Patient age. The prevalence of off-label prescribing can also vary
depending on the age of the child. Schirm, Tobi, & de Jong-van den Berg (2003)
analyzed the outpatient pharmacy records for over 19,000 children aged 16 and
younger in the Netherlands to determine the age of children most likely to receive
a medicine off-label. The authors first compared the medicine's label to the age
of the child to determine if the child was at least the minimum age for use and
then they grouped the results by age (0-1, 2-5, 6-11, and 12-16 years) to
determine the proportions of off-label prescribing per each group. In a total of
66,222 prescriptions, 20.6% were prescribed off-label and children aged 12-16
years old received the greatest percentage of medicines off-label (27.4%) and
children aged 2-5 received the least percentage of medicines off-label (16.4%).
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Conversely, Conroy, Mcintyre & Choonara (1999) determined that off label
drug use is more prevalent in neonates than any other age group. These authors
prospectively collected patient demographic data, diagnosis, and prescription
information for all patients admitted to a neonatal intensive care unit in the United
Kingdom over a 13 week period. In order to determine whether the medicine if
the medicine was prescribed off-label, the researchers compared the patient age,
dose, indication and route of administration to several drug reference sources.
Of a total of 455 prescriptions issued during the study period, 249 (54.7%) were
prescribed in an off-label manner and many were off-label for more than one
reason.
Limitation of prevalence studies. Although varied, the results of studies
described in this section indicate that off-label prescribing is prevalent across
many diagnoses, patient populations, and locations. The variance is at least
partially due to the methods followed during the study to determine the
prevalence of off-label prescribing. For example, some researchers only have
access to the patient age and name of medicine prescribed (e.g. Schirm et aI.,
2003). In this case, if the medication was prescribed off-label because the
dosage did not match the dosage information on the product license, its use
would not be considered off-label. Because of this limitation, the results of most
of the studies presented in this section likely underestimate the magnitude of offlabel drug use.

Concerns of Off-label Prescribing
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While off-label prescribing is legal, it is important for patients and
physicians to understand all the risks and benefits of the practice. The following
section outlines the concerns identified in the literature regarding this practice.
Physician knowledge. According to the FDA, physicians are required to

be well informed about the proper use of a medicine and prescribe it only when
the use is based on "firm scientific rationale or on sound medical evidence"

t

(http://www.fda.gov/oc/ohrtlirbs/offlabel.html. Accessed March 18,2007). Drug
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prescribing manuals, pharmacies, the FDA, and pharmaceutical companies are
all commonly used sources of information regarding the proper use of a
medicine. However, according to Blumer (1999), the Physicians Desk Reference
(PDR), which is the most recognized information source for practitioners in the

United States, is not the best reference. The PDR contains only the drug's
package insert, or label. It does not contain any information on off-label uses, or
in-depth information regarding the safety or tolerance of a medicine. More
specifically, the PDR contains either no pediatric dosing information or explicitly
states that the safety and efficacy of the medicine in children have not been
determined. Therefore, a physician may have difficulty being well informed about
the proper use of a medicine and ensuring the use is based on sound medical
evidence.
Ekins-Daukes, et al. (2005) prospectively surveyed 346 doctors in 80
outpatient practices in Scotland to determine their attitudes and experience with
off-label prescribing to children. Of the 202 (58%) surveys returned, over 70%
indicated that the doctors are familiar with off-label prescribing and 40%
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knowingly prescribe off-label. These results indicate that there are still many
physicians that are not aware of the practice. Interestingly, almost all doctors
surveyed indicated that development of pediatric formulations and clearer
dosage information were the best means to reducing off-label prescribing
indicating that they believe that the current references are not complete.
Lastly, Radley, et al. (2006) analyzed prescription data from the 2001
National Disease and Therapeutic Index (NDTI), a quarterly survey of about
1

II

3,500 US office-based physicians regarding their clinical activity. The authors
studied the prescribing patterns of the NDTI top 100 prescribed medicines as
well as 60 additionally randomly selected medications. Using the patient's
diagnosis, they categorized the prescriptions as prescribed according to the FDA

1
I

j

approved label, off-label with strong scientific support, or off-label with limited or
no scientific support. They found that of the 575 million prescriptions in the
studied sample, 150 million (21 %) were prescribed off-label and 109 million

j
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(73%) medicines prescribed off-label had little or no scientific support.

I

to prescribe medicines based on their knowledge and expertise, they may not

I

always have adequate information to assist them when prescribing a medicine. If

I

I

I

The results of these studies indicate that although physicians are required

physicians cannot rely on approved and published information to make proper
prescribing decisions, then they may subject their patients to unnecessary or

1
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improper treatment.
Patient safety. Patient safety is also a concern when prescribing a
medicine off-label. If the FDA has not approved the medication for the
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prescribed indication, age, dosage or route of administration, then the patient
may experience unknown side effects or the medicine may not work as intended.
Often, children, especially infants, may not be able to swallow a medicine via the
approved route of administration; for example, a tablet versus a liquid.
Therefore, physicians may prescribe a formulation which is not commercially
available and the consequences of the different formulation may not be fully
known. Also, physiologically, pediatric patients react differently to drugs when
compared to adults (Cohen, 1997); side effects are of special concern when a
medicine, approved for adults, is prescribed to children. In these situations,
physicians must prescribe a medicine off-label to the child and the side effects
could produce unintended results for the patient. (Conroy, 2002)
Results of several studies suggest that off-label treatments can lead to a
higher incidence of side effects. Neubert, et al (2004) found that patients treated
with off-label medicines had a much higher risk of developing unwanted side
effects, or adverse drug reactions (ADRs). These researchers prospectively
evaluated patient charts from a German hospital pediatric ward over an 8-month
period. Out of a total of 170 patients given 740 prescriptions, 195 medicines were
prescribed off-label. Of these, 46 ADRs were detected in 31 patients, an overall
ADR rate of 17.4%. Patients that received at least one medicine off-label
experienced at least one ADR more frequently than patients who received a
medicine only in a licensed manner (28.3% vs 7.8%), almost 4 times greater
chance.
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Interestingly, these authors also found that when the physician prescribed
a medicine in an off-label manner, they were more likely to recognize the
associated ADR than when the ADR was associated with a medicine prescribed
in an approved manner (43.8% vs 64.3%). This is an important finding because it
shows that when the physicians prescribed the medicine off-label, they had
increased their awareness level for ADRs, possibly because they were
prescribing the medicine off-label.
A few years earlier, Turner, Nunn, Fielding, and Choonara (1999) had
similar findings in their 13 week prospective study of prescriptions in children's
hospital wards in the United Kingdom. Of 4,455 prescriptions given to 936
patients during the study period, 1,574 (35%) were off-label. ADRs occurred with
6% of the medicines prescribed off-label but only with 3.9% of the licensed
medicines, accounting for an increased risk of about 1.5.
Horen, Montastruc and Lapeyre-Mestre (2002) reported similar, alth()ugh
less alarming, results in their prospective study of pediatric drug prescribing
among 39 office-based physicians in France over a 4 month period. In this
study, 42% of the 1419 patients received at least one off-label prescription and of
those prescriptions, 20 ADRs were reported, with the incidence of ADRs for off
label medicines occurring 2.0% of the time versus 1.4% medicines that were
prescribed according to their label. Most likely, there were much fewer ADRs
reported in this study versus the studies done in the hospital because the
medicines prescribed in the hospital are more powerful as the diseases treated in
the hospital are much more serious.
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If an ADR does occur, physicians may be reluctant to report the ADR
when the medicine was prescribed for an off-label use (Conroy, 2002). Also,
without knowing the ADRs that occur in patients on a widespread basis,
physicians may unknowingly subject their patients to ADRs.

Litigation. Researchers indicate that physicians fear legal complications
if they prescribe a medicine off-label if their patient has an adverse reaction to
the medicine or if the medicine is ineffective for the indication prescribed. Blum
(2002) explains that physicians must be very careful to ensure that the
information they use to prescribe a medicine to their patients is up to date and
scientifically valid. As explained previously, the PDR, while a common reference,
becomes quickly out-of-date and does not include any information about off-label
prescribing. If a physician is unsure about the safety or efficacy of a medicine
when prescribed off-label, they may hold back valuable treatments for the patient
just because the medicine is not approved in the manner it was prescribed
(O'Reilly & Dalal, 2003).
Hill (2005) explains that if a physician did not prescribe the best medicine
for their patient, whether the medicine is prescribed off-label or not, the physician
could be held liable for any side effects that occur. Several legal cases have
sided with patients claiming that physicians have not used good judgment when
prescribing medicines off-label. If a physician is unsure about the latest off-label
research, they may choose to not prescribe medicines off-label, which could
mean that a highly effective treatment is withheld from the patient. In order to be
protected from legal liabilities, physicians must rely on information and guidance
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from "a respected body of medical knowledge." However, as indicated above,
finding a reference that is appropriate is not always easy or feasible for the
physician (Hill, 2005).
Insurance reimbursement. When a physician prescribes a medicine offlabel, the patient may have difficultly getting reimbursement for the medicine.
Many prescription benefit companies will reimburse patients only for medicines
that have been approved by the FDA for the use in which they were prescribed
(O'Reilly & Dalal, 2003). In situations where off-label treatments may be more
effective than approved medicines, insurance reimbursement issues can hinder a
physician's ability to effectively treat a patient. Patients in these situations may
be forced to pay out-of-pocket for their medicines or be treated with medicines
that may be less effective for their needs.
Patient complaints. Lastly, as patients become more educated about
healthcare, they may be more likely to complain to their physician about the use
of a medicine in a manner that is not indicated on the medicine's label.
Physicians, however, want to please their patients. Lowe-Ponsford & Baldwin
(2000) surveyed 200 psychiatrists to determine how common off-label
prescribing was in their specialty and to ascertain whether or not they felt
sufficient prescribing guidelines were available. Although 65% of respondents
indicated that they prescribed medicines off-label in the last month, only four
percent had received complaints from their patients regarding the off-label
prescribing. Although the result is not very significant and the respondents did
not indicate what the exact complaint was, based on respondent comments, the
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authors believe that patient complaints are another concern that may influence
physicians to prescribe a medicine off-label. If patients complain, a physician
may be less likely to prescribe a certain medicine to their patients, even if the
medicines prescribed off-label can benefit the patients more than those
prescribed in a manner indicated on the label.

New Regulations

To encourage manufacturers to perform more clinical trials in the pediatric
population, which would lead to more data about the risks and benefits of the use
of a specific medicine in this population, in 1997, the FDA enacted the pediatric
exclusivity program. This program allows the FDA to grant a patent extension to
a manufacturer if they conduct pediatric clinical trials with their medicines.
Fortunately, there have been over 100 changes made to product labels due to
the new data available on the use of the medicine in the pediatric population.
According to Benjamin, et al. (2006) dissemination of all clinical trial
results has been limited. Their study suggests that the results of clinical trials
with positive results are much more likely to be reviewed by the FDA and
published. These researchers found that positive labeling changes were made
for only 50% of the studies submitted to the FDA and that results from only 45%
of studies performed were published in peer reviewed journals. These results
indicate that although the new regulation has been successful in encouraging
manufactures to perform pediatric clinical trials, the results from the studies are
not being published in a manner to ensure physicians understand all the risks
and benefits of a particular medicine before prescribing it to their patients.
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Pediatrician Opinion
While off-label prescribing is prevalent in many patient populations and
there are many factors associated with the practice, few researchers studied
physician knowledge and attitudes regarding the practice. Moreover, no
research is available which explains whether physicians treating children have
the same factors, knowledge and beliefs regarding the practice as physicians
that treat adults. This study will add to the body of knowledge regarding off-label
prescribing in the pediatric population.

Summary
The practice of prescribing medicines to children in a manner that has not
been approved by a regulatory agency (off-label prescribing) can have significant
effects on the patient, their family and the healthcare community. This literature
review described the process a manufacturer must follow to receive marketing
approval for a medicine, reviewed the prevalence of off-label prescribing in both
the general and pediatric populations and evaluated several concerns of off-label
prescribing.
Physicians, who are ultimately responsible for providing medicines to
patients, must be able to provide patients and their families with adequate,
balanced information on the benefits and risks of all treatment options, whether
the options are approved for the prescribed use or not. In order for this to occur,
physicians must be aware of the risks and benefits of off-label prescribing. In
addition, they must be able to adequately describe it to their patients. Only when
both the physician and the patient are properly informed can they both decide on
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the best treatment method. Therefore, it is important to understand the reasons
why physicians choose to prescribe medicines off-label to children. The results
of this study will provide the background knowledge needed to develop strategies
to ensure that the medication decisions being made for pediatric patients are the
most effective and evidence-based.
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Chapter III

Methods

Subjects
All members of the New Jersey chapter of the American Academy of
Pediatricians (AAP/NJ) and the Tennessee chapter of the American Academy of
Pediatricians (TNAAP) with an email address registered with their respective
organization were asked to participate in the study. The American Academy of
Pediatrics (AAP) is a national organization that is "committed to the attainment of
optimal physical, mental, and social health and well-being for all infants, children,
adolescents and young adults" (http://www.aap.org/about.html. Accessed April
30,2008). They provide membership opportunities to pediatricians, pediatric
medical subspecialists and pediatric surgical specialists.
TNAAP and AAP/NJ offer benefits and have membership similar to AAP,
but at the state level. The members of these organizations were chosen as
subjects for this study because TNAAP and AAP/NJ are the largest groups that
represent the pediatric profession in their respective states. Surveying two states
allowed for a greater number of respondents and enabled the researcher to
determine if pediatrician understanding of off-label prescribing differs based on
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geographic practice location. These particular two states were chosen due to
geographic convenience for the researcher while also representing different
regions of the United States.
The AAP/NJ has 2,184 members and 1,806 of the members have an
email address registered with the organization. TNAAP has 1,100 members and
864 of the members have a working email address registered with the
organization. Not having a working email address registered with either TNAAP
or AAP/NJ when the survey was distributed was the only exclusion criterion for
this study.

In order to achieve a medium effect size of .3, a power of .8 and an

alpha of .05, a minimum of 143 respondents were required (Erdfelder, Faul &
Buchner, 1996; Portney & Watkins (2000».

Design and Variables
This study was a between respondents, descriptive survey design.

Independent variables. The eight independent variables were the
answers to the demographic questions. The answers to these questions
collected general information about the respondents in order to help gain
information which could account for the answers given for the dependent
variables.
The independent variables are the following: (1) name of state in which
the respondent practices medicine [New Jersey, Tennessee or other], (2) name
of country in which the respondent attended medical school, (3) name of country
in which the respondent completed first residency, (4) name of country in which
the respondent completed fellowship, (5) name of country in which the
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respondent obtained board certification, (6) whether the respondent was a
pediatric generalist, surgical specialist or medical specialist, (7) number of years
the respondent has been a practicing physician and (8) the type of environment
the respondent works in [solo practice, group practice, teaching or non-teaching
hospital].
Dependent variables. The thirty-two dependent variables were the

answers to the five research questions. The frequency of use of the 12
references, 11 therapeutic categories and 5 age ranges identified in the first
three research questions each had five levels of responses on a Likert scale: (1)
regularly, (2) often, (3) sometimes, (4) rarely and (5) never. The percent of
medicines prescribed in the last year had 5 possible responses (none, 1-25%,
26-50%,51-75%, and 76-100%). The last three dependent variables, the legal
concerns, patient complaints and personal opinion about off-label prescribing,
had 6 levels of responses on a Likert scale: (1) strongly agree, (2) agree, (3)
neutral, (4) disagree, (5) strongly disagree and (6) I do not prescribe medicines
off-label.
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researcher developed an eleven item survey based on the literature that
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describes factors that may influence physicians to prescribe medicine off-label
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Instrumentation

There are currently no available surveys published to determine
pediatrician attitudes and beliefs towards off-label prescribing. Therefore, the

(Conroy, 2002). Prior to use, in the current study, the survey was distributed to
ten experts in healthcare and research associated with Seton Hall University for
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face validation. Expertise was defined as possessing a terminal doctoral degree
in healthcare or a related field, twenty or more years of experience in research
and the title of Associate Professor or greater. The process utilized for validation
and the changes made to the survey due to the validation process are described
in Appendix A and was based on the Delphi method as described by Hyrkas,
Appelqvist-Schmidlechner, & Oksa (2003), Powell (2003) and Rubio, BergWeger, Tebb, Lee, & Rauch (2003).

Structure of the survey. The final version of the survey is contained in
Appendix B. The survey contained four sections: (1) instructions, (2) research
questions, (3) demographic questions and (4) an open-ended question.

I
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I

The instructions contained a brief consent statement and definitions of
terms used in the survey. The terms defined were off-label, regularly, often,
sometimes, rarely, never, strongly agree, agree, neutral, disagree, and strongly
disagree. The consent statement indicated that by submitting a completed
survey, the participant allowed the researcher to use the answers for research
purposes.
The second section of the survey contained 5 questions about the
knowledge, practice and concerns of pediatricians regarding off-label prescribing.
The first question in this section asked participants to report on the frequency of
use of 12 different medical references when choosing to prescribe a medicine to
their patients. The second question asked participants to indicate their use of
medicines off-label over the last month for 11 different therapeutic categories.
The third question asked participants to indicate their use of medicines off-label
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for 5 different patient age ranges. For each of these first three questions, the
participants were instructed to choose one of the following previously-defined
choices on a Likert scale: (1) regularly, (2) often, (3) sometimes, (4) rarely and
(5) never.
The fourth question asked respondents to report on the percentage of
medicines they prescribed off-label in the last year, ranging from 0 to 100% in
five categories (Le. none, 0-25%, 26-50%, 51-75%, and 76-100%). The final
question in this section contained three individual statements for which
participants were asked to report their beliefs about off-label prescribing with

1

regard to legal liabilities, patient complaints, and whether off-label prescribing

I

should be allowed. The possible responses for these questions were: (1) strongly

I

agree, (2) agree, (3) neutral, (4) disagree, (5) strongly disagree and (6) I do not
prescribe medicines off-label.
The third section consisted of 5 demographic questions. The following
information was collected about the respondents via multiple choice answers:
state in which they practiced medicine, whether specialist or generalist, years
working as a pediatrician, and working environment. In addition, the
pediatricians were asked to provide the name of the country where they attended

I

medical school, completed residency, completed fellowship and obtained board
certification.
The final section of the survey consisted of one open-ended question
which gave the partiCipants an opportunity to share any additional information
about off-label prescribing.

I
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Data Collection
The survey was hosted on SurveyMonkey (www.surveymonkey.com). a
secure website for creating and hosting web surveys. The participants were
required to log on to the website via a unique Universal Resource Locator (URL)
to access the survey. SurveyMonkey.com ensured that there were no duplicate
responses from the same IP address which prevented participants from
completing the form multiple times.
Confidentiality and anonymity were maintained as no personal, identifiable
information about the participants was collected. Participants were unable to
view the responses of other participants or any summary of responses which
could cause bias or pose as a potential influence.
Prior to obtaining approval of the research protocol by the Institutional
Review Board (lRB) for Human Subjects Research at Seton Hall University, the
researcher contacted the Executive Director of the TNAAP and the President of
the AAP/NJ to determine their interest in participating in the study. Both
organizations agreed to participate and provided the researcher with written
approval for their participation. The written approval indicated that the TNAAP
and AAP/NJ staff agreed to be the conduit between the researcher and the
subjects by distributing the survey to all members of their associations that have
an email address registered with their association. They also agreed to send two
reminders, one at two weeks and one at four weeks after the initial invitation, to
all individuals who received the initial invitation (Appendices C and D).
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Following approval by the IRB (Appendix E), the researcher developed
and sent emails (Appendices F, G and H) to the Executive Directors of the
TNAAP and AAP/NJ asking them to forward the email to all members of their
association with email addresses registered with their respective associations.
The emails brielly explained the purpose of the study and invited the recipients to
complete the survey. The emails included a link for the subjects to click on which
brought them to a website, which included the survey instructions, applicable
definitions and the survey. If the email recipient chose to participate, they
completed the survey on-line and submitted their responses to the Survey
Monkey host location.
The first email was sent to both individuals by the researcher on May 14,
2009, the second email was sent May 31,2009 and the final email was sent on
June 15, 2009. While data collection was ongoing, all information collected was
stored on SurveyMonkey.com and only the researcher had access to this
information. The survey was available for access from May 14,2009 to July 6,
2009. After July 6,2009, the researcher downloaded the survey answers
directly from the survey website and saved it to two USB drives, one which
remained in a locked, secure cabinet in the researcher's home office and one
which remained in a locked, secure cabinet in the researcher's professional
office. After analyzing the data using SPSS, the researcher saved all information
related to the study on a CD, in a locked cabinet, in the researcher's home office.
No other people had access to the data.

Data Analysis
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Data obtained from each of the submitted surveys were coded and
downloaded to the Statistical Package for Social Sciences (SPSS) Version 17.0
for data analysis. Prior to analyzing the data, the questions utilizing a Likert
scale were coded. Questions 1-3 were coded as follows: 1= regularly, 2=often,
3=sometimes, 4=rarely and 5=never. Question 5 was coded as follows:
1=strongly agree, 2=agree, 3=neutral, 4=disagree, 5=strongly disagree and 6=1
do not prescribe medicines off-label.

Statistical analysis. The researcher analyzed the data using both
descriptive and non-parametric statistics. With descriptive statistics, the
researcher was able to describe the central tendency and variability of the data to
describe the population (Portney & Watkins, 2000), in this case, the factors that
may affect off-label prescribing. Specifically, frequencies and lor percentages
were reported to examine trends in the following independent variables: years of
practice, specialty, practice type, country educated and practice location. The
results of these tests enabled the researcher to describe the demographics of the
population surveyed. Means and frequencies were calculated to examine trends
in the following dependent variables: off-label prescribing concerns, percentage
of drugs prescribed off-label in the last year, therapeutic categories of off-label
prescriptions, references used, and age range(s) of patients.
Two non-parametric statistics, the chi-square test of association and
Spearman's rho, were used to analyze the relationships of the variables in this
study. The chi-square test examines the association between the variables and
cross tabulations were used to describe the association of many variables at one
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time. Spearman's rho, used to determine relationships among ordinal data, was
used to analyze the relationships between the dependent variables in this study
(Portney & Watkins, 2000).
The Chi Square tests analyzed relationships between the independent
and dependent variables {e.g. whether or not pediatricians educated outside of
the United States prescribe more medicines off-label than those educated in the
United States}. The Spearman's rho tests analyzed the relationships between
the dependent variables (e.g. whether or not pediatricians with more concerns
about off-label prescribing prescribe medicines off-label less often than
pediatricians that have less concerns about off-label prescribing).
An alpha level of pS.05 was considered significant for all statistical tests
(Portney & Watkins, 2000).

Analysis of responses to open ended question. The qualitative data
received from the last question of the survey were analyzed for emergent
themes, which were then compared with the quantitative data received from the
other survey questions. In addition, keyword analysis and topic grouping was
used to analyze the response to the open ended question in order to develop
future research questions and enable the researcher to interpret the qualitative
data with respect to the quantitative data.
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Results

Study Sample
Of the 2670 email requests to participate in the survey, a total of 167
individuals accessed the survey and responded to at least one survey question
(response rate = 6.25%). As indicated earlier, 143 responses were required
based on the power analysis. Because respondents were not required to provide

I

answers to all survey questions, all surveys submitted, regardless of whether all
questions were answered, were included for analysis.
Demographic characteristics of the study sample. The demographic
characteristics of the study sample (years in practice, specialty, practice type,
country educated and location of practice) were analyzed using means, standard
deviations and frequencies. The demographics of the study sample were then
compared to the questions regarding off-label use to determine if there are any
relationships between the demographics and beliefs and practices regarding offlabel prescribing.
Almost two-thirds of the respondents indicated that they practice medicine
in Tennessee (n=104, 62.3%), 58 (34.7%) indicated that they practice in New
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Jersey, 3 respondents (1.8%) indicated another state and 2 respondents (1.2%)
did not respond to the question (Figure 2).
Figure 2. State in which respondents practice medicine
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The number of years, post residency, that the respondent has been a
practicing physician is shown in Figure 3. Twenty-five (15%) respondents had
less than 5 years of experience, forty-six (27.5%) had 5-15 years of experience,
fifty-two (31.1 %) had 15-25 years of experience and thirty-six (21.6%) had over
twenty-five years of experience. Seven respondents (4.2%) indicated they were
residents and one respondent (0.6%) did not answer the question.

Figure 3. Number of years respondent has been a practicing physician
(post residency)
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Regarding pediatric specialty, the majority (n=119, 71.3%) of respondents
reported that they were pediatricians, with no specialty. Forty respondents (24%)
indicated that they were pediatric medical subspecialists, and 3 respondents
(1.8%) indicated that they were pediatric surgical specialists. One respondent
(0.6%) indicated that they were an administrator in a pediatric hospital and one
respondent indicated that they were a pediatric resident. Three respondents did
not answer this question.
Regarding their working environment, six percent of respondents (n=10)
indicated they worked in a solo practice, 51.5% (n=86) in a group non-hospital
based practice, 7.8% (n=13) in a non-teaching hospital based practice and
33.5% (n=56) in a teaching-hospital based practice. Because respondents were
allowed to select more than one answer, the total number of responses for this
question exceeds the total number of respondents.
The majority of the respondents reported that they attended medical
school in the USA (n=145, 86.8%). The remainder of the respondents attended
medical school in 14 other countries which are listed in Table 1.
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Table 1. Country in which respondents attended medical school
Country
No answer
Brazil
Colombia
Czech Republic
Germany
Grenada
India
Jordan
Lebanon
Mexico
Nigeria
Pakistan
Philippines
Saint Kitts
USA
West Indies
Total

Freguenc~

Percent

1
2
2
1
1
2
3
1
1
1
2
1
2
1
145
1
167

0.6
1.2
1.2
0.6
0.6
1.2
1.8
0.6
0.6
0.6
1.2
0.6
1.2
0.6
86.8
0.6
100

One hundred sixty three (97.6%) respondents indicated that they
completed their first residency in the USA. One respondent did not answer the
question and three other respondents indicated that they completed their first
residency in other countries, namely Brazil, India and Lebanon.
About half of respondents (n=76, 45.5%) indicated not applicable to the
question regarding where they completed their fellowship. Twenty-one
respondents (12.6%) did not provide an answer to this question and 70
respondents indicated that they completed their fellowship in the USA. As
fellowships are not required in all medical specialties, the response to this
question was not surprising.
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The majority of respondents also indicated that they obtained board
certification in the USA (n=155, 92.8%). The remainder of the respondents either
indicated not applicable (n=9, 5.4%) or did not provide a response to this
question (n=3, 1.8%).
Overall, therefore, the study population reflects general pediatrician
population in the United States in terms of specialty, practice type, number of
years respondents practiced medicine, and the country in which the respondents
attended medical school, completed first residency and completed their first
fellowship and was Board Certified (Smart, 2009).

Frequency of Off-label Prescribing
Figure 4 indicates that almost three quarters of the respondents (73.1 %)
prescribed medicines off-label 1-25% of the time in the last year.
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Figure 4. Frequency of percent of off-label prescriptions in the last year
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Use of References for Medication Prescribing
Respondents reported that, most often (43% indicated regularly used),
they use reference manuals to determine which medicines to prescribe to their
patients (mean 1.92, indicating an average ranking of often) and that they use
unpublished research least often (49% indicated never used) for determining
whether to prescribe a medicine to their patients (mean 4.41, indicating an
average ranking between rarely and never).
The other references, ranked from greatest to least used, are as follows:
published, peer-reviewed research (mean 1.96), medicine's label (mean 2.01),
previous experience (mean 2.01), group! hospital! facility! office's experience

1
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(mean 2.20), peer recommendations (mean 2.46), pharmaceutical representative
(3.54), patient's insurance company (mean 3.59), patient! guardian's request
(mean 3.61), published, not-peer reviewed research (mean 3.68), and patient I
guardian's suggestion (mean 3.74).
Interestingly, the references with the least consistency in use (highest
standard deviation) were the medicine's label and the patient's insurance
company, with standard deviations of 1.078 and 1.191, respectively. Table 2
provides detailed information on the number of respondents who used each
referenced resource to determine whether to prescribe a medicine to their
patients and their individual means and standard deviations.
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Table 2. Materials respondents use to determine whether or not to

prescribe medicine to their patients
I use the following to determine whether or not to
prescribe medicine to my patients:

N

Mean

Standard
deviation

The medicine's label

162

2.01

1.078

Published, peer-reviewed research

164

1.96

0.929

Reference manuals

166

1.92

0.956

Published, not peer-reviewed research

161

3.68

0.885

Unpublished research

162

4.41

0.665

My previous experience with the medicine

164

2.01

0.95

My group/ hospital! facility / office's experience
with the medicine

163

2.2

0.995

Peer recommendations

163

2.46

0.884

Information from a pharmaceutical representative

162

3.54

0.985

The patient's insurance company

161

3.59

1.191

The patient / guardian's suggestion

163

3.74

0.736

The patient / guardian's request

162

3.61

0.798

Off-label Prescribing by Therapeutic Area
Of all the therapeutic areas included in the survey, respondents reported
that they prescribe antibiotic medicines in an off-label manner, most often (mean
3.63, indicating an average ranking between sometimes and rarely) and insulin,
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least often (mean 4.90, indicating an average between rarely and never but very
close to never).
The other therapeutic areas, which were ranked from greatest to least
prescribed off-label, are as follows: anti-asthmatic (mean 3.75), anti-histimifle
(mean 3.80), dermatologic (mean 3.90), analgesic (mean 3.96), rhinological
(mean 4.23), expectorant and anti-tussive agents (mean 4.27), otologic (mean

4.44), psycholeptic and psychoanaleptic (mean 4.48), and anti-epileptic (mean
4.51 ).
The therapeutic area with the highest noted standard deviation was anti
asthmatic, at 1.294. This indicates that this therapeutic area had the most
variability in response around the mean. The therapeutic area with the least
variability was insulin, .361, indicating little variability in responses around the
mean. Table 3 indicates the frequency that the respondents prescribe medicines
off-label for each therapeutic area and their individual means and standard
deviations.
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Table 3. Medicines prescribed off-label in various therapeutic areas once

1

l

per month, at minimum (total n= 164)

1
J

1

Therapeutic area

~

N

Mean

Standard Deviation

analgesic

164

3.96

1.164

!,

anti-asth matic

164

3.75

1.294

I~

anti-epileptic

164

4.51

0.825

antibiotic

163

3.63

1.176

anti-histimine

162

3.8

1.098

dermatologic

162

3.9

1.061

expectorant and anti-tussive agents

163

4.27

0.889

insulin

164

4.9

0.361

otologic

164

4.44

0.736

psycholeptic and psychoanaleptic

163

4.48

0.958

rhinological

163

4.23

0.938
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Off-label Prescribing by Age
When asked what age ranges respondents prescribed medicines off-label
to in the last month, there was no significant difference in the means and
standard deviations for the different age ranges provided less than 18 years of
age. The mean for less than one year old was 3.52, for 1-5 years old was 3.43,
for 6-12 years old was 3.50, and for 13-17 years old was 3.55, which all indicate
an average ranking between sometimes and rarely. The standard deviations
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were 1.320, 1.136, 1.116 and 1.093, respectively, which indicates that there was
some variability around the mean for these age ranges.
For patients 18 years and older, the mean was 4.07, indicating an average
ranking of 4.07, between rarely and never, and the standard deviation was .944,
indicating less variance around the mean than for all other age ranges.

Off-label Prescribing Beliefs
Regarding their beliefs about off-label prescribing, with a mean of 2.90,
respondents reported that they felt slightly concerned about legal liabilities or
were neutral in their response. The standard deviation, however, was 1.288,
indicating some variance around the mean.
Respondents indicated that they disagree that they are concerned about
patient or guardian complaints when they prescribe a medicine off-label or were
neutral in their response (mean 3.59). The standard deviation for this question
was 1.110, indicating some variability around the mean.
Respondents indicated that they believe that physicians should be allowed
to legally prescribe medicines off-label, as the mean for the question "I believe
that physicians should not be legally allowed to prescribe medicines off-label"
was 4.23, with the average ranking between disagree and strongly disagree. The
standard deviation was 1.118, indicating some variability around the mean.

Nonparametric Statistical Analysis
The Chi-square test of association was used to analyze relationships
between the dependent and independent variables using cross tabulations.
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Spearman's Rho was used to analyze the relationships between the dependent
variables. Only the analyses that met the criteria for statistical significance of
p~.05

are described in this section.
The first set of analyses conducted were to determine if there was a

relationship between the state in which the respondent practiced medicine and
the following dependent variables: materials respondents use to determine
whether to prescribe a medicine to their patient, medicines in various therapeutic
areas respondents prescribed off-label in the last month, respondents beliefs
regarding off-label prescribing and the percent of medicines the respondents
prescribed off-label in the last month.
Regarding materials used to determine whether to prescribe a medicine
to their patients, there was a significant relationship between state in which the
respondents practiced medicine and the medicine's label (p=.021), the
respondent's group/ hospital! facility / office's experience with the medicine
(p=.021) and peer recommendations (p=.OOO).
The only therapeutic area in which the respondent's state and whether the
respondent prescribed medicines off-label in that therapeutic area in the last
month had a statistically significant relationship was for analgesic medicines
(p=.006). The only belief that had a statistically significant relationship with the
respondent's state was legal liabilities (p=.011).
The second set of analyses conducted were to determine if there was a
relationship between the therapeutic area of medicines prescribed off-label and
the pediatric specialty (pediatrician, medical subspecialist or surgical
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subspecialist) of the respondent. For this analysis, two therapeutic areas met the
criteria for statistical significance of p:5.05: whether the respondent prescribed
expectorant and anti-tussive agents off-label in the last month (p=.011) and anti
histirnine medicines (p=.01 0).
For all these associations, the results must be interpreted with caution, as
there were numerous cells that had a count of less than 5 responses per cell J3nd
with such a small number of responses, the results may not be indicative of the
beliefs of the general population.

Qualitative Analysis
Since there is little research available which looks at off-label prescribing
from the prescriber's point of view, the last question of the survey asked
respondents to include any additional information they would like the researcher
to consider about off-label prescribing. The themes that emerged from the
responses allowed the researcher to put the quantitative responses into context
as well as develop further avenues to pursue when studying off-label prescribing
(Graneheim & Lundman, 2004).
A total of 40 respondents provided comments to the last question of the
survey. The responses were grouped into seven categories based on keywords
within the responses.
The first category contained a total of 13 responses that indicated that
either the respondent was a specialist and the majority of the medicines they
prescribe are off-label or that the respondent was a general pediatrician that
relied heavily on specialists for prescribing medicines off-label to their patients.
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An example of a response in this category was '" do weight heavily the off-label
use of medications by pediatric subspecialists in deciding whether it is either safe
or efficacious to use a particular medication. It would seem that the
subspecialists are the "first to choose a drug for off-label use. If it is successful in
the patients I have referred to them, and if I see increasing numbers of patients
being treated that way, I am more likely to try it off-label myself."
The second category contained 11 responses in which respondents
indicated that they believe that the majority of the off-label prescribing that they
engage in is related to the age of their patient. They further indicated that they
rely on evidence-based data on adults to assist them in determining whether they
should prescribe a medicine to their child, indicating that they attempt to use an
evidence-based approach to making their prescribing decisions.
The third category that emerged from respondents' comments supported a
disappointment with the lack of evidence-based data regarding the use of many
medications in the pediatric population. Specifically, five respondents indicated
that while they do not like prescribing off-label to their patients, they feel forced to
because of the lack of approved medications in this population. An example of a
response in this category was "it is difficult to find enough drugs approved for the
less than 12 month old."
The fourth category contained responses from 4 respondents. These
respondents indicated that they prescribe only certain medicines off-label to their
patients given they can based their prescribing decision on their previous
experience with the medication thus supporting that prior knowledge does playa
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key factor in prescribing practices. An example of a response in this category
was "I prescribe hydroxyurea to children with sickle-cell disease on a regular
basis because, based on my experience, it is effective for these patients."
Interestingly, only two respondents indicated that they do not inform the
patient or their guardian when they prescribe medicines off-label to them and
also do not discuss the medication risks and potential other options of care. This
suggests that communication may be factor in decision making for some
physicians.
Only, one respondent indicated that they were not aware what medicines
were off-label anymore. Two respondents provided non-content specific
responses to this question: one further clarified their use of the word rarely for
responding to the survey questions and one respondent indicated that their
answers to the survey may have been different if they were still practicing
medicine.

Summary

A total of 167 individuals provided answers to an on-line survey regarding
their beliefs and practices toward off-label prescribing.
The hypotheses that pediatricians would report that the primary factors
that influence their decision whether or not to prescribe a medicine off-label are a
lack of appropriate references and concerns about patient safety and the
secondary factors that influence their decision whether or not to prescribe a
medicine off-label are legal concerns, insurance coverage and patient complaints
were not fully supported by the results of this study.
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Interestingly, respondents indicated that they use reference manuals most
often, with published, peer-reviewed research a close second. These results are
promising because, as indicated in chapter 2, the problem with reference
manuals is that they may not contain the most up-to-date research regarding a
medicine and published, peer-reviewed research is the best way to supplement.
Additionally, this may offer support that physicians are aware of the need to
practice in an evidenced based manner using the currently available evidence to
support and direct their clinical decision making.
However, given the significant variance (1.078) in the use of the
medicine's label for prescribing information, one must question their practices as
the drug's label contains the most up-to-date information about the health
authority-approved uses for the medicine. Thus, this finding may suggest that
some respondents may not be prescribing a medicine in a manner not approved
by a health authority.
Regarding their beliefs about off-label prescribing, respondents did not
feel strongly about the legal liabilities or patient complaints related to off-label
prescribing but did believe that physicians should legally be allowed to prescribe
a medicine off-label.
Yet, given that almost two-thirds (73%) of respondents indicated that, in
the last year, they prescribed medicines off-label less than 25% of the time and
none of the therapeutic areas listed in the survey supported that they prescribed
off-label medications regularly or often, off-label prescribing does not seem to be
prevalent in this physician population. Taken together, this data suggests that
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pediatricians prefer to practice autonomously using and evidence-based
approach which may explain why they do not prescribe medicines off-label a
significant portion of the time regardless of practice setting.
Considering that most of the respondents were not medical or surgical
specialists and many worked in an outpatient facility, the overall results of the
study are not surprising. As indicated in chapter 2, medicines are prescribed off
label more often for the more serious, specialized diseases where the patient is
typically seen in the hospital or by a specialist (O'Reilly and Dalal, 2003) and,
therefore, the pediatricians working in these areas are more likely to prescribe
medicines off-label and have concerns about the practice.
While the results of the quantitative questions within the survey provided
valuable insight into the beliefs and practices of pediatricians toward off-label
prescribing, the answers to the qualitative question were similarly revealing.
Many respondents indicated that they believed that the references currently
available were inadequate and that, often, pediatricians rely on specialists to
prescribe medicines off-label. This finding is also in line with previous research
that indicates that generalists often do not prescribe medicines off-label (O'Reilly
and Dalal, 2003).
The qualitative findings of this study support previous literature that
indicates that there is a need for more research in the pediatric population. In
addition, the results indicate that pediatricians are concerned about the safety
and efficacy of the medicines they prescribe to their patients and would like to
have evidence-based results prior to prescribing a medicine to their patient.
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Certainly if a medicine is prescribe in the manner indicated on its label, then that
means that it has been tested and found to be safe and effective.
As the results of this study indicate, pediatricians have concerns about
prescribing a medicine off-label because information about the proper use of the
medicine may not be available. With the absence of evidence-based research,
pediatricians must utilize their critical thinking skills and develop practice based
evidence to determine the best medicine to treat their patient (Horn & Gassaway,

2007).
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Chapter V

Discussion and Conclusions
The purpose of this study was to determine pediatrician beliefs toward off
label prescribing and the factors that may influence their decision to prescribe a
medicine off-label. The results of this study indicate that pediatricians prescribe
medicines off-label and most reported that they do so no more than 25% of the
time. Respondents also indicated that some pediatricians have little experience
with off-label prescribing and, often, there are no references, based on evidence
-based practice, that clearly define how medicines should be prescribed off
label.
The results of this exploratory study set the stage for the initial dialogue
regarding off- label prescribing practices in the pediatric population in a scholarly
venue. While this contribution, in of itself. is important to the practice of health
care in the United States, this work sheds light on the importance of the health
care community specifically physicians, who as autonomous practitioners have
the right and privilege to prescribe medications off-label, to practice their craft
using the best available evidence.
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Two key factors that can be used to support evidenced based practice
which resonate from the findings of this study are the importance of practice
based evidence and ongoing training for health care professionals.

Practice-based Evidence

One way to address the lack of evidence-based practice is to develop
guidelines based on observed current practices. Horn and Gassaway (2007)
describe this method as practice-based evidence (PBE). PBE is developed by a
multisite, trans-disciplinary Clinical Practice Team whose responsibility is to
analyze patient data within their practice to develop guidelines for members of
their clinical team. The team does not need to publish the data or rely on others
to approve their guidelines; they just need to ensure there is observable evidence
to justify the processes suggested.
Other benefits of PBE are that the data that is analyzed is based upon
patient treatments and therapeutic outcome data that is normally collected in
medical practice and therefore, does not require patient consent. Also, the
guidelines developed can be modified quickly based on new information,
evidenced based observations or treatment outcome data. Thus, health care
team does not need to wait for regulatory approval or the publication of evidence
based practices; the team can re-train and improve their practices as necessary
based upon PBE.

Training
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Training is another issue that was highlighted in the results of this study.
Many physicians felt that additional training is needed to determine the risks and
benefits related to off-label prescribing as well as when the practice is
appropriate or not. The issue is how to develop training that will be effective.,
Generally, after the completion of their internship, any and all training that a
physician receives is through continuing medical education (CME) (Davis, 1998).
Several studies (Holm, 1998; Fox & Bennett, 1998; Mathers, Challis, Howe &
Field, 1999; Grol, 1992; Bashook & Parboosingh, 1998) present theories for how
to effectively and efficiently provide CME to physicians as well as how to change
a physician's prescribing behavior through CME (Denig, Wahlstrom, Chaput de
Saintonge, Haaijer-Ruskarnp, 2002; Gill, Makela, Verneulen, Freemantle, Ryan,
Bond, et ai, 1999).
Interestingly, Verniga, Denig, Zwaagstra, and Haaijer-Ruskamp (2000)
studied the effects of cognitive feedback on a physician's choice of treatment for
patients with asthma and urinary tract infections. Their parallel, randomized
controlled study included 24 already existing pharmacotherapy counseling
groups in the Netherlands, each with about 7 physicians per group. The
researchers provided half of the groups with national guidelines, case studies
and individual and group feedback on the prescribing choices made for the
treatment of asthma and half of the groups received this information of urinary
tract infections (UTls). Each set of groups acted as a control group for each
condition.

Lastly, the researchers collected the 6 months of prescribing data
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before the intervention and 6 months of prescribing data after the intervention to
determine whether there were any changes in prescribing behaviors.
While the results of this study showed some improvement in prescribing
behaviors, they showed no significant improvement in participants' knowledge.
The intervention for the asthma groups did not, on average, improve participants'
knowledge of the condition, yet there was an 11% to 68% improvement for the
treatment of different patients with asthma (e.g. treating with inhaled vs. oral
steroids). For the UTI groups, there was little improvement in knowledge of the
disease or treatment choices but there was a significant effect on the duration of
treatment (decreased from an average of 6.07 to 4.29 days on treatment.) This
suggests that although physicians may have sufficient knowledge about a
condition, providing them with approved guidelines and feedback on appropriate
prescribing can improve their prescribing behavior.
Another way to change pediatrician prescribing behavior is described by
Fox and Bennett (1998) and is based on adult learning theory. They suggest that
in order to influence a change in physician behavior, physicians need to first
identify the deficiencies in their own knowledge and experience and then critically
evaluate the new information to influence the change. Ultimately, the physicians
must believe that they need to change their behavior in order to effectively
practice. They explain that the motivation comes from a physician who estimates
where they should be in terms of knowledge or skills and then compares it to
what they actually know or do. Surprisingly, only if the physician discovers a
discrepancy do they become motivated to learn and address that gap in their
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knowledge. Thus, leaving change in the hands of the physician who may not be
aware of their limitations, but who has the right and privilege to prescribe off 
label. Hopefully, if more research is made available that describes the risks and
benefits of off-label prescribing as well as off-label practicing patterns, physicians
may self-reflect upon their knowledge of, comfort of and current off-label
practices and see it as an area to improve their prescribing practices.

Clinical Judgment Analysis
Once PBE is established and effective training programs are developed, a
pediatrician, or any health care professional, ultimately needs to include the new
practices into their decision making processes for prescribing. The Clinical
Judgment Analysis model, as described by Denig, Wahlstrom, Chaput & Haaijer
(2002), indicates one way in which PBE and training would influence prescribing
decision making practices. The Clinical Judgment Analysis model (Figure 5)
indicates that there are several informational cues that enable a physician to
make a decision. These cues can be a patient's signs or symptoms, laboratory
test results, patient preferences, etc. The model suggests that each individual
physician weighs the relative importance of each of the information cues
differently based on their knowledge of what the optimal decision is versus their
own personal experience or knowledge and then makes the final judgment or
decision.
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Figure 5. Clinical Judgment Analysis Model
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As suggested above and further explained by Denig, et al (2002). the key
to clinical judgment analysis is the knowledge and expertise of the physician
regarding the specific decision that needs to be made. The authors believe that
the Clinical Judgment Analysis Model looks behind the outcome of a decision to
the underlying decision process and combines ideas from adult learning,
behavioral change and decision making theory to improve prescribing decisions.
Both PBE and effective training could lead a physician to support their final
prescribing decision because they can assist them in reflecting on the influence
and relevance of the information cues. If off-label prescribing is included as an
additional informational cue in the clinical judgment model then it can further
support a physician in making a better prescribing decision for their patient.
Finally, the authors suggest that educators could develop a set of case
studies with informational cues for physicians to analyze. Using the case study
approach further insight on the physicians use of the cues in order to make
prescribing decisions could be explored and thus further support the adult
learning process via feedback to the physician. In the literature it has been
suggested that through this direct feedback that physicians learned and were
able to make changes to their prescribing behavior. These findings support the
possibility that case studies can be effectively used in a similar fashion to inform
and educate the decision making practices of pediatricians with regard to off
label practices. Specifically, physicians could be provided with a set of case
studies, based on PBE, which present various situations where off-label
prescribing may be necessary. Then, through the analysis of the case studies,
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pediatricians could determine the best options for their patients, thus creating
PBE and establish effective training on that practice.
Overall, the results of our study and those in the literature support that
while no single strategy can change a physician's behavior, the most successful
strategies are based on the theories of adult learning and behavioral change that
require physicians to critically think about and analyze their decisions. Clearly,
these findings further explain our data in a meaningful manner and offer insight
into future directions for research and education. Given that the respondents of
this study indicated that they had varying levels of years of experience practicing
medicine and the absence of significant differences in off-label prescribing
practices among the different levels of experience one might suggest that aCME
course that included an element for developing their critical thinking skills, could
assist pediatricians, at all levels of experience, in critically reviewing and
assesses all e evidence available to support that use, whether it is EBP or PBE.

Limitations
The respondents that completed the survey represented a convenience
sample of volunteers who learned about the survey through their membership of
either the AAP/NJ or TNAAP. While about two-thirds of the respondents
indicated that they practice medicine in TN and about one-third in NJ, the survey
results may not be representative of the views or practices of other pediatricians
who are members of these organizations or, furthermore, of those that practice
medicine in NJ or TN.
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One of the limitations of this study was the difference in size between the
number of specialists and general pediatricians. As the qualitative results
indicated, some generalists rely on the specialists to prescribe medicines off
label. Since 119 of the respondents were general pediatricians and only about
45 of the respondents were specialists, it was not ideal to calculate group
differences since the sizes of the groups were so disparate.
Another limitation involved the use of an anonymous, on-line survey to
collect the data. Although Surveymonkey.com prevented the same person from
answering the survey using the same computer by blocking their IP address after
they completed the survey, this could have been circumvented by use of an
alternate computer. The anonymity also prevented the researcher from verifying
the answers from each of the respondents. Specifically for the questions that
required respondents to recall their prescribing patterns over the last month or
the last year, chart verification could have yielded more accurate results. The
questions which used a Likert scale assumed that the categories had equal
intervals between them, which is unlikely. Lastly, the use of a survey inherently
is a limitation because surveys only collect perceptions I opinions and may not
accurately reflect the behaviors of the respondents.

Future Research
The purpose of this research study was to determine the beliefs and
factors that may influence a pediatrician to prescribe medicines off-label. The
results of this study should be used to encourage pediatricians to seek more
guidance and training on the best use of off-label prescribing practices. The
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results of future research involving a larger population, face to face interviews
with pediatric specialists or chart reviews could further support the findings of this
study_
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Abstract

Published literature indicates that the prescribing of off-label
medicines to children is common. However, few researchers have surveyed
pediatricians to determine their attitudes and beliefs toward this practice and no
surveys used in these studies have been validated by research and healthcare
experts. The purpose of this research project was to develop and validate a
survey that will be used to determine the attitudes and beliefs of New Jersey
pediatricians towards off-label prescribing. Ten experts were asked to comment
on the appropriateness, clarity and sequence of the survey questions. Seven
experts responded to the request. Overall, only minor changes were
incorporated into the survey.
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Introduction
A medicine that is prescribed off-label is prescribed in a manner that has
not been approved by a health authority. Although off-label prescribing is legal,
many researchers have expressed concerns about the use of medicines in this
manner, indicating that medicines prescribed off-label may not be safe and/or
effective. These concerns are especially common in the pediatric population
because of the significant physiological changes occurring in the pediatric
population (Cohen, 1997).
Several studies have been performed globally to indicate the prevalence
of off-label prescribing in the pediatric population. Results of these studies
indicate that up to 63% of medicines prescribed to children are off-label
(Pandolfini & Bonati, 2005). Researchers suggest several reasons for the
widespread use of off-label medicines in this population such as lack of
resources to perform clinical trials in this population (Conroy, 2002) and lack of
appropriate references and training on how to properly medicate children
(Matsui, Jardine, Steer, Cukernik & Rieder, 2003). However, only two studies
indicate the attitudes and beliefs of physicians towards this practice (Ekins
Daukes, Helms, Taylor & McLay, 2004 and McLay, Tanaka, Ekins-Daukes &
Helms, 2006). Because the physician ultimately provides the prescription to the
patient, it is important that their perspectives of off-label prescribing are properly
understood by those wanting to make changes to this practice.
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The Elkins-Daukes et al and McLay et al studies include the results of a
survey given to over 200 general practitioners in Scotland indicating their
attitudes and beliefs towards off-label prescribing. However, neither study details
the methods used to develop and validate the survey tool used to collect the
study data. Therefore, it is important that a survey used to determine the
attitudes and beliefs of pediatricians towards off-label prescribing is developed
and properly validated by experts in research and healthcare.

Methods
A survey consisting of instructions, 5 research questions, 5 demographic
questions and 1 open ended question for additional comments was developed
based on the review of published research in the area of off-label prescribing to
children (Appendix 1). Each question contains multiple choice, Likert-scale or
open ended answers. Validation of the sequence, appropriateness,
completeness and clarity of the survey questions was obtained by mailing printed
copies of the survey to ten experts in healthcare and research affiliated with
Seton Hall University. Expertise were defined as possessing a terminal degree
in healthcare or related field, 20 or more years of experience in research and a
title of associate professor or greater.
Along with a copy of the survey, an introduction letter (Appendix 1) was
provided which included a brief summary of the purpose of the study, definitions
of terms and references used in the survey, and the researcher's contact
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information in case the expert had questions about the survey. The experts were
asked to answer 2-4 questions per survey question, each allowing the expert to
report whether the sequence, appropriateness, completeness and clarity of the
questions were suitable for the study. Each question for the experts contained
two possible answers - yes and no. If the response was no, the experts were
asked to provide suggestions for improvement. A self-addressed stamped
envelope was included along with the survey and the experts were asked to
return completed surveys back within 2 weeks of receipt. Seven responses were
received within the study timeframe. Overall, only a few questions have been
changed due to the survey validation results. The final survey can be found in
Appendix 2.

Results
Analysis
Below are summaries of the responses per question. Only responses
received by two or more experts (29% or more) were considered for revision.

Survey Instructions
Five experts (71 %) believed that the survey instructions were both
appropriate and clear. Two experts (29%) did not comment on the
appropriateness or clarity of the survey instructions. No experts believed that the
instructions should change in any manner; therefore, the instructions remained
unchanged in the final version of the survey.

f
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Question 1. The purpose of question 1 was to determine the reference(s)
pediatricians use to prescribe medicines to their patients. The experts were
asked whether the question was appropriate for the study, clear, in the correct
sequence and complete. All but one expert provided answers for this question.
Six respondents (86%) believed question 1 was appropriate for this
survey. Only one respondent believed that question 1 was not clear. Two
experts (29%) believed that the sequence of the statements in question 1 were
not suitable. Both experts suggested that the list be presented in order from
least scientific I evidence-based to most scientific I evidence-based. Because
two experts reported this opinion, meeting the previously set criteria for making
changes to the survey, the sequence of the answers for this question has been
changed in the final version of the survey.
Two experts believed that additional references should be added to
question 1. One expert suggested that the Merck Manual be added to the list
and the other believed that Personal Digital Assistants (PDAs) should be added.
Because these suggestions do not meet the previously set criteria of two experts
providing the same suggestion, the reference list will remain unchanged in the
final version of the survey.

Question 2. The purpose of question 2 was to determine the therapeutic
categories pediatricians most often prescribe medications in an off-label manner.
The experts were asked whether the question was appropriate for the study,
clear, in the correct sequence and complete. One expert (14%) did not provide
answers for this question.
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Six experts (86%) believed that question 2 was appropriate for this survey.
Only one expert (14%) believed that question 2 was not clear. Because this
response was received by only one expert, the question will remain unchanged.
One respondent (14%) believed that the therapeutic areas should be
presented in alphabetical order. Four experts (57%) suggested that additional
categories should be added to the question. The suggestions included anti
anxiety, anti-inflammatory, and a section for Other. One expert questioned the
use of psychotropic, however, did not explain why so no changes are being
made to this term. The suggested categories have not been added to the final
version of the survey because only one expert made the suggestion for each
therapeutic category.

Question 3. The purpose of question 3 was to determine the age ranges
treated by the pediatricians who complete the survey. The experts were asked
whether the question was appropriate for the study, clear, and in the correct
sequence. Two experts (29%) did not provide answers for this question.
Five (71%) experts believed that this question was both appropriate and in
the correct sequence for this survey. Only one expert (14%) believed that
question 3 was not clear. Because this response was received by only one
expert, the question will remain unchanged in the final version of the survey.

Question 4. The purpose of question 4 was to determine the percent of
medicines the pediatrician prescribed off-label in the last year. The experts were
asked whether the question was appropriate for the study, clear, and in the
correct sequence. Two experts did not provide answers for this question.
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Five experts (71 %) believed that this question was both appropriate and in
the correct sequence for this survey. Three experts (43%) believed that question
2 was not clear. One expert asked whether this question needs to be qualified
by age group as in question 3. One expert suggested to change the ranges for
choices b-e from 1-25,25-50,50-75 and 75-100% to 1-5,5-10, 10-25, and >25%
and another expert suggested to change the ranges to 1-25,26-50,51-75 and
76-100%.
Although none of these suggestions were made by more than one expert,
the criteria established for making changes to the final version of the survey, the
final version will be changed to reflect the latter suggestion. This change
ensures that the answers are distinct from one another.

Question 5. The purpose of question 5 was to determine the beliefs that
pediatricians have about off-label prescribing. The experts were asked whether
the question was appropriate for the study, clear, in the correct sequence and
complete. One expert did not provide answers for this question.
Five (71 %) experts believed that this question was appropriate for this
survey. Because only one expert (14%) believed that changes should be made
to the question, the question will remain unchanged.
Six (86%) experts believed that the question was both clear and in the
correct sequence. Two experts (29%) made suggestions for additional
statements to be added to this question. The first suggestion was to add
questions regarding the ethical implications of off-label prescribing (e.g. patient
safety, informed consent) and the second was to add a statement saying "I
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believe that patients should receive pharmacotherapy that presents the best
outcome opportunity regardless of label use."

Because the suggestions for this

question were not received by two or more experts, meeting the previously
defined criteria, this question will remain unchanged.

Question 6. The purpose of question 6 was to determine in which state
the pediatrician practices medicine. The experts were asked whether the
question was appropriate for the study, clear, and in the correct sequence. Two
experts (29%) did not provide answers for this question. The remaining experts
(71 %) believed that this question was appropriate, clear and in the correct
sequence for this survey.

Question 7. The purpose of question 7 was to determine the country the
pediatrician attended medical school, completed residency, completed fellowship
and obtained board certification. The experts were asked whether the question
was appropriate for the study, clear, in the correct sequence and complete.
One expert (14%) did not provide answers for all questions; two experts
(29%) did not provide responses for the last question. Six experts (86%)
believed that the question was appropriate, clear and in the correct sequence for
the survey. Two experts (29%) believed that additional options should be added
to this question. One expert suggested that an option is added to allow for more
than one residency. The other expert suggested to add an option to determine
whether the pediatrician is a currently a licensed practitioner. Because both of
these suggestions were made by only one expert each, the final version of the
survey will remain unchanged.
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Question 8. The purpose of question 8 was to determine whether the
respondent is a general pediatrician, pediatric medical specialist or pediatric
surgical specialist. The experts were asked whether the question was
appropriate for the study, clear, in the correct sequence and complete.
Two experts (29%) did not provide answers for the questions regarding
appropriateness; the remainder of the experts (71 %) did believe that the question
was appropriate. Two experts (29%) did not comment on the clarity of this
question and four experts did believe that the question was clear. One expert
believed that choices b & c should include a section for the respondents to write
in their specific specialty. However, since this comment was received by only
one expert, question 8 will remain unchanged.
Four (57%) experts did not answer the question about sequence, while the
remainder of the experts did believe that the question was in the correct
sequence. None of the experts provided suggestions for additional options to
this question.
Question 9. The purpose of question 9 was to determine the number of
years the respondent has been a practicing physician. The experts were asked
whether the question was appropriate for the study, clear, and in the correct
sequence.
One expert (14%) did not provide a response for this question. Six experts
(86%) believed that this question was appropriate and in the correct sequence.
Two experts (29%) did not believe that this question was clear. One expert
suggested that the words "post residency" be added to the question. Although
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only one expert provided this comment, this phrase will be added to the final
version of this survey to ensure that survey respondents all use the same
definition for practicing physician.
One expert questioned whether practice experience, specifically for
pediatricians who have been practicing for 5-15 years, would skew the results of
this study; however, this expert did not provide a suggestion for improvement.
Because this response was received from only one expert, the final survey will
remain unchanged.

Question 10. The purpose of question 10 was to determine the working
environment of the survey respondent. The experts were asked whether the
question was appropriate for the study, clear, and in the correct sequence.
Two experts (29%) did not provide an answer for the question about
appropriateness. The remainder of the experts, however, did believe that this
question was appropriate for this survey. One expert did not provide a response
for the questions about clarity or sequence. Four experts (57%) believed that the
question was clear; two experts (29%) provided suggestions for improving the
clarity.
Specifically, one expert believed that option b (group practice) should be
separated into 3 categories - 2-10, 11-25 and greater than 25 doctors. The other
expert suggested that an additional option be included for "other." Because
neither suggestion was provided by two or more experts, this question will remain
unchanged in the final version of the survey.
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Question 11. The purpose of question 11 was to determine whether the

pediatricians have any additional information about off-label prescribing to share
with the researcher. The experts were asked whether the question was
appropriate for the study, clear, and in the correct sequence.
Two experts (29%) did not answer the question about appropriateness;
three experts (43%) did not answer the questions about clarity and sequence.
The remainder of the experts believed that this question was appropriate (71 %).
clear (57%) and in the correct sequence (57%). Therefore, this question will
remain unchanged.
Additional suggestions. Experts were also provided the opportunity to

make additional suggestions to improve the survey. One expert believed that an
additional question could be added on the policy of off-label use in the given
organization. The expert believed that the policies of the pediatrician's
organization may have a larger impact on prescribing practices of the pediatrician
than the individual pediatrician's attitudes and beliefs toward off-label prescribing.
Because this comment was received by only one expert, no changes will be
made to the final version of the survey based on this comment.
An additional suggestion provided by an expert was that the research
question uses the term influence, implying causality, and that this survey does
not measure causality. No changes will be made to the final version of the
survey based on this comment because it was received by only one expert.
Results Summary
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Only three changes were made to the survey based on the input from the
experts. The first change was to the sequence of the answers in question 1. In
the final version of the survey, the answers will be provided in order from most
scientific to least scienti'flc, as suggested by two experts.
Another change was made to improve the clarity of the answers for
question 4. Instead of overlapping the choices (i.e. 1-25, 25-50, 50-75 and 75
100), the final version of the survey will provide clearly distinct possibilities for the
respondent (i.e. 1-25,26-50,51-75 and 76-100).·
The wording of question 9 was changed to improve the clarity as well. The
words "post residency" will be added to the final version of the survey to ensure
that all respondents answer the question in the same manner.
Appendix 1 contains the introduction letter and survey that was sent to the
experts. Appendix 2 contains the final version of the survey, based on the
responses from the experts. Overall, the survey did not change greatly from its
initial format. The information that was changed between the two versions is
indicated in italics.

Conclusion
The purpose of this paper was to describe the development and validation
of a survey to be used to determine New Jersey pediatrician attitudes and beliefs
towards of off-label prescribing. The survey was developed after a thorough
review of published literature describing the issues associated with off-label
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prescribing. Validation of the survey was performed by experts in healthcare and
research to ensure that the survey was appropriate, clear and information was
presented in the proper sequence.
Survey validation allows the researcher to ensure that the survey will
adequately capture the appropriate information necessary to conduct the
research. Overall the experts believed that the survey was clear and appropriate
and that the questions were presented in the correct sequence. Only minor
changes were made to the final version of the survey and all were made to
improve the clarity of the survey. All changes are highlighted in Appendix 2.
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Appendix 1

Survey Sent to Experts

September 12, 2006
Dear Healthcare Educator:
I am a doctoral student at Seton Hall University in the School of Graduate
Medical Education. Your name was provided to me as an expert in healthcare
and research by Dr. Genevieve Pinto-Zipp, chair, Graduate Programs in Health
Sciences. I would appreciate your input on the appropriateness, clarity and
sequence of the questions in the attached survey. After the final version of the
survey has been developed, a sample of pediatricians in New Jersey will be
invited to participate in its completion, via email, over the internet.
The purpose of the study is to determine the factors influencing
pediatricians in prescribing medicines off-label. Off-label prescribing occurs
when a physician prescribes a medicine in a manner where the dosage, age,
indication and/or route of administration have not been approved by a health
authority (not indicated on the medicine's label).1 While off-label prescribing is a

I Conroy, S. (2002). Unlicensed and off-label drug use: issues and recommendations. Pediatric Drugs, 4
(6),353-359.
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legal and widely accepted practice, up to 33% of children in the community, up to
60% of children in a pediatric hospital ward and up to 63% of children in a
neonatal hospital ward receive medicines off-label.

2

Please provide your responses and comments in the grey box below each
question on the enclosed survey. Please also use the following definitions when
providing your feedback:
Appropriate: The survey question and answers are suitable for this study.
Clear: The survey question and answers are easy to understand.
Sequence: The survey questions and answers are presented in a logical
order.
Your thoughtful response to this request should take no longer than 20
minutes. Please return your comments in the enclosed envelope, addressed to
Joann DeBerto, secretary, Seton Hall Graduate Programs in Health Science, no
later than September 26, 2006. If you would like to complete your review
electronically, please email your request to me at herbstel@shu.edu. Upon
completion of the data analysis, the final results of the study will be provided to
you.
Sincerely,
Elizabeth G. Evola

2 Pandolfini, C. & Bonati, M. (2005). A literature review on off-label drug use in children. European
Journal ofPediatrics, 164,552-558.
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Survey Instructions
By completing this survey, you consent for the researcher to use your
answers for research purposes. Please use the following definitions when
responding to the survey questions:

Off-label: A medicine prescribed in a manner where the dosage, age,

indication

and/or route of administration are not indicated on the medicine's

label (have

not been approved by a health authority).3

Regularly: I perform this activity greater than 75% of the time.
Often: I perform this activity greater than half but less than 75% of the time.
Sometimes: I perform this activity greater than 25% but less than half of the
time.
Rarely: I perform this activity less than 25% of the time.
Never: I do not perform this activity.

Are these instructions appropriate for this survey, yes or no?
If no, what are your suggestions for improvement?

Are these instructions clear, yes or no?
If no, what are your suggestions for improvement?
!

Survey Questions

J Conroy, S. (2002). Lnlicensed and otT-label drug use: issues and recommendations. Pediatric Drugs, 4
(6),353-359.
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1) I use the following to determine whether or not to prescribe medicine to my
patients:

Regularly Often

i

Sometimes Rarely Never

Reference Manuals (e.g.
Physicians Desk Reference
(PDR»
Patient / guardian suggestion
Patient / guardian request
Patient insurance company
My previous experience with
the medicine
My group/ hospital! facility/
office's experience with the
medicine
The medicine's label
(prescribing information)
Published research
Unpublished research
Peer recommendations
Information from
pharmaceutical representative

i

Is Question #1 appropriate for this survey, yes or no?
If no, what are your suggestions for improvement?

Is Question #1 clear, yes or no?
If no, what are your suggestions for improvement?

Is Question #1 in the correct sequence, yes or no?
If no, what are your suggestions for improvement?

Are there any other references that should be included in the list in Question #1,
yes or no?
If yes, name them here.

!

i

i
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2) Once per month, at minimum, I prescribe medicines in the following
categories in an off-label manner.

Regularly

Often

Sometimes

Rarely

Never

Dermatologics
Otologics
Psycholeptic and
psychoanaleptics
Analgesics
Rhinologicals
Antihistamines
Expectorants and anti
tussive agents
Anti-epileptics
Anti-asthmatics
Antibiotics
Insulin

Is Question #2 appropriate for this survey, yes or no?
If no, what are your suggestions for improvement?

I

Is Question #2 clear, yes or no?
If no what are your suggestions for improvement?

I

Is Question #2 in the correct sequence, yes or no?
If no, what are your suggestions for improvement?

Are there any other medicinal categories that should be included in the list in
Question #2, yes or no?
If yes, name them here.

3) Once per month, at minimum, I prescribe medicines to patients in the
following age ranges in an off-label manner.

Never
Less than 1 ear old
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1-5 years old
5-12 years old
13-18 years old
Greater than 18 years
old

Is Question #3 appropriate for this survey, yes or no?
If no, what are your suggestions for improvement? .

Is Question #3 clear, yes or no?
If no, what are your suggestions for improvement?
..

Is Question #3 in the correct sequence, yes or no?
If no, what are your suggestions for improvement?

4) In the last year, what is the percent of medicines that you prescribed off
label?
a) None
b) 1- 25 %
c) 25 - 50%
d) 50 - 75%
e) 75 - 100%

Is Question #4 appropriate for this survey, yes or no?
If no, what are your suggestions for improvement?

Is Question #4 clear, yes or no?
If no, what are your suggestions for improvement?

Is Question #4 in the correct sequence, yes or no?
If no, what are your suggestions for improvement?

I

':"
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5) Although the practice of medicine allows for physicians to prescribe
medicines off-label, please complete the following section with regard to your
beliefs about off-label prescribing.

Strongly
Agree

Agree

Neutral

Disagree

Strongly
Disagree

I do not
prescribe
medicines
off-label.

When I
prescribe a
medicine offlabel, I am
concerned
about the legal
liabilities.
When I
prescribe a
medicine offlabel, I am
concerned that
patients (or
their guardians)
will complain.
I believe that
physicians
should not be
legally allowed
to prescribe
medicines offlabel.

Is Question #5 appropriate for this survey, yes or no?
If no, what are your suggestions for improvement?

Is Question #5 clear, yes or no?
If no, what are your suggestions for improvement?

Is Question #5 in the correct sequence, yes or no?
If no, what are your suggestions for improvement?

Are there any other options that should be included in the list in Question #5, yes
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6) In what state do you practice medicine?
a) New Jersey
b) Other _ _ _ _ _ __

Is Question #6 appropriate for this survey, yes or no?
If no, what are your suggestions for improvement?

Is Question #6 clear, yes or no?
If no, what are your suggestions for improvement?

Is Question #6 in the correct sequence, yes or no?
If no, what are your suggestions for improvement?

7) In which country did you:

United States

If outside United
States, enter
name of
country.

Attend Medical
School?
Complete
Residency?
Complete
Fe"owship?
Obtain Board
Certification?

Is Question #7 a ro riate for this surve , es or no?
If no, what are our su

Not applicable
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Are there any other options that should be included in the list in Question #7, yes
or no?
.
.
If es, nam~them .here.

8) Are you a: (please choose only one answer)
a.) Pediatrician
b.) Pediatric medical subspecialist
c.) Pediatric surgical specialist

Is Question #8 appropriate for this survey, yes or no?
If no, what are your suggestions for improvement?

Is Question #8 clear, yes or no?
If no, what are your suggestions for improvement?

Is Question #8 in the correct sequence, yes or no?
If no, what are your suggestions for improvement?

Are there any other options that should be included in the list in Question #8, yes
• or no?
i If yes, name them here.

9) How many years have you been a practicing physician?
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a.
b.
c.
d.

Less than 5 years
5-15 years
15-25 years
greater than 25 years

Is Question #9 appropriate for this survey, yes or no?
If no, what are your suggestions for improvement?

Is Question #9 clear, yes or no?
If no, what are your suggestions for improvement?

Is Question #9 in the correct sequence, yes or no?
If no, what are your suggestions for improvement?

10) What type of environment do you currently work in? (please choose all that
apply)
a.)
b.)
c.)
d.)

Solo practice
Group practice
Hospital based practice - non-teaching
Hospital based practice - teaching

Is Question #10 appropriate for this survey, yes or no?
If no, what are your suggestions for improvement?

Is Question #10 clear, yes or no?
If no, what are your suggestions for improvement?

Is Question #10 in the correct sequence, yes or no?
If no, what are your suggestions for improvement?
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11) Please provide any additional information about your off-label prescribing
practices for the researcher to consider.

Is Question#11 appropriate for this survey. yes or no?
If no, what are your suggestions for improvement?.k·
; ..
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Is Question #11 clear, yes or no?
".
If no, what are your suggestions for improvement?

.......

,~

.

•.......

:'.
.....

"

.

Is Question #11 in the correct sequence, yes or no?
If no, what are your suggestions for improvement?

1
i

1
~

1
1

In thespacebelow. please provide al1~additionalsugges\ions for this surveyr:,
Thank you for your time in completihg"this survey.;;
.•.
.

Please send any additional comments to me using the enclosed envelope
or email me at herbstel@shu.edu.
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Appendix 2

Final Survey

Survey Instructions
By completing this survey, you consent for the researcher to use your
answers for research purposes.

Please use the following definitions when responding to the survey
questions:

Off-label: A medicine prescribed in a manner where the dosage, age,
indication and/or route of administration are not indicated on the medicine's
label (have not been approved by a health authority).4

Regularly: I perform this activity greater than 75% of the time.
Often: I perform this activity greater than half but less than 75% of the time.
Sometimes: I perform this activity greater than 25% but less than half of the
time.

4 Conroy, s. (2002). Unlicensed and off-label drug use: issues and recommendations. Pediatric Dnlgs, 4
(6),353-359.
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Rarely: I perform this activity less than 25% of the time.
Never: I do not perform this activity.

Survey Questions

1) I use the following to determine whether or not to prescribe medicine to my
patients:

Regularly

Often

Sometimes

Rarely

Never

Reference Manuals (e.g.
Physicians Desk Reference
(PDR), etc.)
Published research
Unpublished research
The medicine's label
(prescribing information)
My previous experience with
the medicine
My group/ hospital/ facility/
office's experience with the
medicine
Peer recommendations
Information from
pharmaceutical representative
Patient insurance company
Patient / guardian suggestion
• Patient / guardian request

i

I

2) Once per month, at minimum, I prescribe medicines in the following
categories in an off-label manner.

Regularly
Analgesics
Anti-asthmatics
I Anti-epileptics
Antibiotics
Antihistamines
Dermatologics

Often

Sometimes

Rarely

Never
I

112
Expectorants and anti
tussive agents
Insulin
Otologics
Psycholeptic and
psychoanaleptics
Rhinologicals

3) Once per month, at minimum, I prescribe medicines to patients in the
following age ranges in an off-label manner.

Regularly

Often

Sometimes

Rarely

Never

Less than 1 year old
1-5 years old
5-12 years old
13-18 years old
Greater than 18 years
old

4) In the last year, what is the percent of medicines that you prescribed off
label?
a) None
b) 1- 25 %
c) 26-50%
d) 51 - 75%
e) 76 100%

5) Although the practice of medicine allows for physicians to prescribe
medicines off-label, please complete the following section with regard to your
beliefs about off-label prescribing.

Strongly
Agree

Agree

Neutral

Disagree

Strongly
Disagree

I do not
prescribe
medicines
off-label.

When I
prescribe a
medicine offlabel, I am
•
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concerned
about the legal
liabilities.
When I
prescribe a
medicine off
label, I am
concerned that
patients (or
their guardians)
will complain.
I believe that
physicians
should not be
legally allowed
to prescribe
medicines off
label.

6) In what state do you practice medicine?
a) New Jersey
b) Other _ _ _ _ _ __

7) In which country did you:

United States

If outside United
States, enter
name of
country.

Attend Medical
School?
Complete First
Residency?
Complete
Fellowship?
Obtain Board
Certification?

8} Are you a: (please choose only one answer)
a.) Pediatrician
b.) Pediatric medical subspecialist
c.) Pediatric surgical specialist

Not applicable

i
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9) How many years have you been a practicing physician (post residency)?
a.) Less than 5 years
b.) 5-15 years
c.) 15-25 years
d.) Greater than 25 years

1

I
!

I

1
!
!

!

10) What type of environment do you currently work in? (please choose all that
apply)
a.) Solo practice
b.) Hospital based practice - non-teaching
c.) Hospital based practice - teaching

I

I
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I
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I

I
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11) Please provide any additional information about your off-label prescribing
practices for the researcher to consider.

115

Appendix B

Final Survey

Survey Instructions
By completing this survey, you consent for the researcher to use your answers
for research purposes.

Please use the following definitions when responding to the survey questions:

Off-label: A medicine prescribed in a manner where the dosage, age, indication
and/or route of administration are not indicated on the medicine's label (have not
been approved by a health authority).5

Regularly: I perform this activity greater than 75% of the time.
Often: I perform this activity greater than half but less than 75% of the time.
Sometimes: I perform this activity greater than 25% but less than half of the
time.

Rarely: I perform this activity less than 25% of the time.

5 Conroy, S. (2002). Unlicensed and off-label drug use: issues and recommendations. Pediatric Drugs. 4
(6),353-359.
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Never: I do not perform this activity.

Strongly Agree: I agree most or all of the time.
Agree: I agree some of the time.
Neutral: I neither agree nor disagree.
Disagree: I disagree some of the time.
Strongly Disagree: I disagree most or all of the time.

Survey Questions

1. I use the following to determine whether or not to prescribe medicine to my
patients:
Regularly Often
The medicine's label
(prescribing information)
Published, peer-reviewed
research
Reference Manuals (e.g.
Physicians Desk Reference
(PDR), etc.)
Published, not peer-reviewed
research
Unpublished research
My previous experience with
the medicine
My group! hospital! facility!
office's experience with the
medicine
Peer recommendations
Information from
pharmaceutical represent
Patient insurance company
Patient! guardian suggestion
Patient! guardian request

Sometimes Rarely

Never
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2. Once per month, at minimum, I prescribe medicines in the following
categories in an off-label manner.

Regularly Often

Sometimes Rarely Never

Analgesics
Anti-asthmatics
Anti-epileptics
Antibiotics
Antihistamines
Dermatologics
Expectorants and anti-tussive
agents
Insulin
Otologics
Psycholeptic and
l??ychoa nal e ptics
Rhinologicals

3. Once per month, at minimum, I prescribe medicines to patients in the
following age ranges in an off-label manner.
Regularly

Often

Sometimes Rarely

Never

Less than 1 year old
1-5 years old
5-12 years old
13-18 years old
Greater than 18 years
old

4. In the last year, what is the percent of medicines that you prescribed offlabel?
•

None

•

25 %

•

26 - 50%
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•

51 - 75%

•

76 - 100%

5. Although the practice of medicine allows for physicians to prescribe
medicines off-label, please complete the following section with regard to your
beliefs about off-label prescribing.

Strongly
Agree

Agree

Neutral

When I
prescribe a
medicine offlabel, I am
concerned
about the legal
liabilities.
When I
prescribe a
medicine offlabel, I am
concerned that
patients (or
their guardians)
will complain.
I bel ieve that
physicians
should not be
legally allowed
to prescribe
medicines offlabel.

6. In what state do you practice medicine?
•

New Jersey

Disagree Strongly
Disagree

I do not
prescribe
medicines
off-label.

1
I

J
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I
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•

Tennessee

•

Other - - - - - - 

!

7. In which country did you:
United States

If outside United
States, enter name
of country.

Not applicable

Attend Medical School?
Complete First
Residency?
Complete Fellowship?
Obtain Board
Certification?

8. Are you a: (please choose only one answer)
•

Pediatrician

•

Pediatric medical subspecialist

•

Pediatric surgical specialist

•

Other - - - - - - -

9. How many years have you been a practicing physician (post residency)?
•

Less than 5 years

•

5-15 years

•

15-25 years

•

Greater than 25 years

•

I am a resident

•

None of the above
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10. What type of environment do you currently work in? (please choose all that
apply)
•

Solo practice

i

1

•

Group non-hospital based practice

1

I

•

Non-teaching hospital based practice

1

•

Teaching hospital based practice

l•
!

'I.

!

j
i1

11. Please provide any additional information about your off-label prescribing
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practices for the researcher to consider.
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i
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TNAAP Approval
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November 4, 2008
Dear Ms. Catherine M. Fenner:
I am a doctoral candidate at Seton Hall University, School of Health and
Medical Sciences and my dissertation topic is pediatric off-label prescribing
practices.
The purpose of my dissertation research is to determine pediatrician offlabel prescribing practices. Off-label prescribing occurs when a physician
prescribes a drug in a manner where the dosage, age, indication and/or route of
administration are not approved by a health authority (not indicated on the drug's
label) (Conroy, 2002).
This confirms our conversation on <<date», that you will send an email
invitation to complete an online survey, which I created and validated (Appendix
1), to the membership of the American Academy of PediatriCS, Tennessee
Chapter (TNAAP). The survey will be placed on wwwJormsite.com, a surveyhosting website, which allows the members of your organization to complete it
online and anonymously. The completion of the survey should take no longer
than 10 minutes and will be available on the 1Nebsite for two months.
I will send you the initial invitation (Appendix 2) for your membership once
the Seton Hall University Institutional Review Board (lRB) has approved my
study. In addition, two weeks and four weeks after the initial invitation is sent, I

will provide you with a follow-up invitation (Appendix 3) for all members of
TNAAP who received the initial email.

f
J

1
1
1
i

ii
"J
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As a token of my appreciation, please contact me at the email address
below and I would be pleased to provide the results of my study to you or your
membership. when available. Thank you, in advance, for your assistance with
this study.

Sincerely.
Elizabeth G. Evola
ElizabethEvola@yahoo.com

8658249433

rf you concur with this request. please sign and date this letter and return the
original copy to me in the envelope provided. Again. thank you for your interest
in the project.

J

Catherine M. Fenner, Execu1ive Director

'

Date
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Appendix D

NJAAP Approval
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November 12. 2008
Dear Dr. Segarra:

I am a doctoral candidate at Seton Hall Uni

rsity, School of Health and

Medical Sciences and my dissertation topic is
practices.
The purpose of my dissert.Qtion research Is

0

d.rmine pediatrician off·

label prescribing practices. Dff-label prescribing ccurs when a physician
prescribes a drug in a manner where the dosage,

e, indicutfon and/or route of

administration are not approved by a health autho "ty (no1lndicated on the drug's

label) (Conroy. 2002).
This confirms our conversation on Novem
an email Invitation to completa an online survey,

r 12. 2008. that you will send
Ich I created and validated

(Appendix 1). Co the membership of the New Jers y Chapter of the American
Academy of Pediatrics (AAPINJ). The survey Will e placed on

www.formslte.com. II survey-hosting website. whl

allows the members of your

organization to complete it online and anonymous y. The completion of the
survey should take no longer than 10 minutes an will be available on the

website for two monti'll.

I will send you the initial Invitation (Appeodi 2) for your membership once
the Seton Hall University Institutional Review Boa

(IRS) has approved my

study. In addition, two Meks and four weeks aft
will provide you with a follow-up invitation (Appen ix 3) for all members of
TNAAP who received the initial email.
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As 8 token of my appreciation, please con
below and I would be pleased to provide the rnu

me at the email address
of my study to you or your

membership. when available. Thank you, in adYB ee, for your assistance with
this study.

Sincerely,
Elizabeth G. Evola

ElizabethEvola@yahoo.com
865824 9433

If you concur with this request. please sign and d te this letter and return it to me.

Again, thank you for your interest in the proj~.

j~c4~
~. Micha::Seg~
AAP/NJ President

November 13. 2008
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Appendix E

Seton Hall University IRB Approval
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REQUEST FOR APPROVAL OF RESEARCH, DEMONSTRATION OR
RELATED ACTIVITIES INVOLVING HUMAN SUBJECTS
All material must be typed.
Off-label Prescribing: Pediatrician Beliefs and

PROJECT TITLE:

E;.>sP~[ifl.QqL-

CERTIFICATION STATEMENT:

In making this application, I(we) certify that I(we) havG read and understand the University's policies and procedures
governing research, development, and related activities involving human subjects. I (we) shall comply with the letter
and spirit of those policies. l(we) further acknowledge my(our) obligation to (1) obtain written approval of significant
deviations from the originally-approved protocol BEFORE making those deviations, and (2) report immediately all
adverse effects of the study on Ihe subjects 10 the Director of the Institutional Review Board, Seton Hall University,
§'outh Orange, NJ 07079.
(;;- li.f "L.() ! ):1'"f'i J ( ... , . .' J~

;~;i~~ ~~~.~ .~ >", ,.

f,

"'Please print or type out names of aU researchers below signature.
Use separate sheet of paper, if necessary...

My Signature indicates that I have reviewed the attached materials and consider them to meet IRB standards.

DA~/c27-"Please print or type out name below signature"

The request for approval submitted by the above resi2'Lcher(s) wss considered by the IRB for Research
Involving Human Subjects Research.aHl're I...tv I ~
~

2.oq

/

_~t

The appticalig;;! was approved
approved _._ by the Committee. Special conditions were _ _
were not . / set by tlle IRB. (Any special condilions are described on the reverse side.)

~f
rr .f.. .

DIRECTOR,

til .0_, --

SETON HALL UNIVERStTY tNSTI
TIONI\L
REVIEW f30AI\O FOR HUMAN SUBJECTS RESE.~RCII

Seton Hall University
312005
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Appendix F

Initial Survey Invitation

Dear Pediatrician:
I am a Doctoral Candidate at Seton Hall University in the School of Health
and Medical Sciences and I am studying pediatric off-label prescribing practices.
You are receiving this email via the email distribution of the New Jersey or
Tennessee chapter of the American Academy of Pediatrics.
The purpose of the study is to determine pediatrician off-label prescribing
practices. Off-label prescribing occurs when a physician prescribes a drug in a
manner where the dosage, age, indication and/or route of administration have
not been approved by a health authority (not indicated on the drug's label)
(Conroy, 2002).
The survey has been designed so that you can complete it anonymously
via the following link: <link will be included here>. It should take no longer than
10 minutes of your time.
Your assistance is greatly appreciated and your response can be provided
anonymously and will be kept confidential. As a token of my appreciation, please
contact me at the email address below and I will provide the results of my study
to you, when available.
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Sincerely,
Elizabeth G. Evola
ElizabethEvola@yahoo.com
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Appendix G

Two week follow-up Survey Invitation
Dear Pediatrician:
This email is a follow-up to an email that you received two weeks ago.
am a Doctoral Candidate at Seton Hall University in the School of Health and
Medical Sciences and I am studying pediatric off-label prescribing practices. You
are receiving this email via the email distribution of the New Jersey or Tennessee
chapter of the American Academy of Pediatrics.
If you have already responded to my survey, I thank you very much for
your time. If not, I would greatly appreciate it if you could assist me in my
research by completing the short survey. As I explained in my previous email, I
am looking to determine the attitudes and beliefs of pediatricians towards off
label prescribing, a practice that occurs when a physician prescribes a medicine
in a manner that has not been approved by a health authority (i.e. not indicated
on the drug's label) (Conroy, 2002).
The survey allows you to complete it anonymously via the following link:
<link will be included here>. It should take no longer than 10 minutes of your
time.
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Your assistance is greatly appreciated. If you have already responded to
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my survey, again, I thank you very much for your time.
Sincerely,
Elizabeth G. Evola
ElizabethEvola@yahoo.com
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Appendix H

Four week follow-up Survey Invitation
Dear Pediatrician:
This email is a follow-up to an email that you received about one month
ago. I am a Doctoral Candidate at Seton Hall University in the School of Health
and Medical Sciences and I am studying pediatric off-label prescribing practices.
You are receiving this email via the email distribution of the New Jersey or
Tennessee chapter of the American Academy of Pediatrics.
If you have already responded to my survey, I thank you very much for
your time. If not, I would greatly appreciate it if you could assist me in my
research by completing the short survey. As I explained in my previous email, I
am looking to determine the attitudes and beliefs of pediatricians towards off
label prescribing, a practice that occurs when a physician prescribes a medicine
in a manner that has not been approved by a health authority (i.e. not indicated
on the drug's label) (Conroy, 2002).
The survey allows you to complete it anonymously via the following link:
<link will be included here>. It should take no longer than 10 minutes of your
time.

134
Your assistance is greatly appreciated. If you have already responded to
my survey, again, I thank you very much for your time.
Sincerely,
Elizabeth G. Evola
ElizabethEvola@yahoo.com

